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Yo
DrAs I spent countless hours pouring over hundreds of manuscripts to select those that rose to the top over the past
year, I became incredibly excited about being part of a Journal that produces such wonderfully rich and diverse
content each year. I have personally selected the papers (both original investigations and review articles) from
13 distinct specialties for your review. There are approximately 150 articles selected across this 2-part series,
which represents less than 3% of the papers submitted to JACC in 2014. In order to present the full breadth of
this important research in a consumable fashion, we will present these manuscripts over the course of 2 issues of JACC.
Part One includes the sections: Congenital Heart Disease, Coronary Disease & Interventions, Genetics, Omics, & Tissue
Regeneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies. Part Two includes the sections:
Hypertension, Imaging, Metabolic Disorders & Lipids, Neurovascular & Neurodegenerative Disorders, Rhythm Disorders,
Valvular Heart Disease, and Vascular Medicine (1–86).HYPERTENSION
2014 Hypertension Recommendations From the
Eighth Joint National Committee Panel Members
Raise Concerns for Elderly Black and
Female Populations
L.R. Krakoff, et al.
A report from panel members appointed to the Eighth
Joint National Committee titled “2014 Evidence-Based
Guideline for the Management of High Blood Pressure
in Adults” has garnered much attention due to its
major change in recommendations for hypertension
treatment for patients $60 years of age and for their
treatment goal. In response, certain groups have
opposed the decision to initiate pharmacologic
treatment to lower blood pressure (BP) at systolic
BP $150 mm Hg and treat to a goal systolic BP of <150
mm Hg in the general population age $60 years. This
paper contains 3 sections—an introduction followed by
the opinions of 2 writing groups—outlining objections
to or support of maintaining this proposed strategy in
certain at-risk populations, namely African Americans,
women, and the elderly. Several authors argue for
maintaining current targets, as opposed to adopting
the new recommendations, to allow for optimal
treatment for older women and African Americans,ten to this manuscript’s audio summary by JACC Editor-in-Chief
. Valentin Fuster.
u can also listen to this issue’s audio summary by JACC Editor-in-Chief
. Valentin Fuster.helping to close sex and race/ethnicity gaps in
cardiovascular disease morbidity and mortality (1).
Impact of the 2014 Expert Panel
Recommendations for Management of High
Blood Pressure on Contemporary Cardiovascular
Practice: Insights From the NCDR
PINNACLE Registry
W.B. Borden, et al.
BACKGROUND Since 2003, the Seventh Report of the
Joint National Committee (JNC-7) has been the pre-
dominant guideline for blood pressure management.
A 2014 expert panel recommended increasing the
blood pressure targets for patients age 60 years and
older, as well as those with diabetes or chronic kidney
disease.
OBJECTIVES The purpose of this study was to
examine the effect of the 2014 expert panel blood
pressure management recommendations on patients
managed in U.S. ambulatory cardiovascular practices.
METHODS Using the National Cardiovascular Data
Registry PINNACLE Registry, we assessed the pro-
portion of patients who met the 2003 and 2014 panel
recommendations, highlighting the populations of
patients for whom the blood pressure goals changed.
RESULTS Of 1,185,253 patients in the study cohort,
706,859 (59.6%) achieved the 2003 JNC-7 goals. Using
the 2014 recommendations, 880,378 (74.3%) patients
were at goal. Among the 173,519 (14.6%) for whom
goal achievement changed, 40,323 (23.2%) had a
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702prior stroke or transient ischemic attack, and 112,174
(64.6%) had coronary artery disease. In addition, the
average Framingham risk score in this group was 8.5
 3.2%, and the 10-year ASCVD risk score was 28.0 
19.5%.
CONCLUSIONS Among U.S. ambulatory cardiology
patients with hypertension, nearly 1 in 7 who did not
meet JNC-7 recommendations would now meet the
2014 treatment goals. If the new recommendations
are implemented in clinical practice, blood pressure
target achievement and cardiovascular events will
need careful monitoring, because many patients for
whom the target blood pressure is now more
permissive are at high cardiovascular risk (2).
2014 Eighth Joint National Committee Panel
Recommendation for Blood Pressure Targets
Revisited: Results From the INVEST Study
S. Bangalore, et al.
BACKGROUND The 2014 Eighth Joint National Com-
mittee panel recommendations for management of
high blood pressure (BP) recommend a systolic BP
threshold for initiation of drug therapy and a thera-
peutic target of <150 mm Hg in those $60 years of age,
a departure from prior recommendations of <140
mm Hg. However, it is not known whether this is an
optimal choice, especially for the large population
with coronary artery disease (CAD).
OBJECTIVES This study sought to evaluate optimal
BP in patients $60 years of age.
METHODS Patients 60 years of age or older with CAD
and baseline systolic BP >150 mm Hg randomized to a
treatment strategy on the basis of either atenolol/hy-
drochlorothiazide or verapamil-SR (sustained release)/
trandolapril in INVEST (INternational VErapamil SR
Trandolapril STudy) were categorized into 3 groups on
the basis of achieved on-treatment systolic BP: group 1,
<140 mm Hg; group 2, 140 to <150 mm Hg; and group
3, $150 mm Hg. Primary outcome was ﬁrst occurrence
of all-cause death, nonfatal myocardial infarction (MI),
or nonfatal stroke. Secondary outcomes were all-cause
mortality, cardiovascular mortality, total MI, nonfatal
MI, total stroke, nonfatal stroke, heart failure, or
revascularization, tabulated separately. Outcomes for
each group were compared in unadjusted and multiple
propensity score–adjusted models.
RESULTS Among 8,354 patients included in this
analysis with an accumulated 22,308 patient-years of
follow-up, 4,787 (57%) achieved systolic BP of <140
mm Hg (group 1), 1,747 (21%) achieved systolic BP of
140 to <150 mm Hg (group 2), and 1,820 (22%)
achieved systolic BP of $150 mm Hg (group 3). Inunadjusted models, group 1 had the lowest rates of
the primary outcome (9.36% vs. 12.71% vs. 21.32%;
p < 0.0001), all-cause mortality (7.92% vs. 10.07% vs.
16.81%; p < 0.0001), cardiovascular mortality (3.26%
vs. 4.58% vs. 7.80%; p < 0.0001), MI (1.07% vs.
1.03% vs. 2.91%; p < 0.0001), total stroke (1.19% vs.
2.63% vs. 3.85%; p <0.0001), and nonfatal stroke
(0.86% vs 1.89% vs 2.86%; p<0.0001) compared with
groups 2 and 3, respectively. In multiple propensity
score–adjusted models, compared with the reference
group of <140 mm Hg (group 1), the risk of
cardiovascular mortality (adjusted hazard ratio [HR]:
1.34; 95% conﬁdence interval [CI]: 1.01 to 1.77;
p ¼ 0.04), total stroke (adjusted HR: 1.89; 95% CI:
1.26 to 2.82; p ¼ 0.002) and nonfatal stroke (adjusted
HR: 1.70; 95% CI: 1.06 to 2.72; p ¼ 0.03) was increased
in the group with BP of 140 to <150 mm Hg, whereas
the risk of primary outcome, all-cause mortality,
cardiovascular mortality, total MI, nonfatal MI, total
stroke, and nonfatal stroke was increased in the group
with BP $150 mm Hg.
CONCLUSIONS In hypertensive patients with CAD
who are $60 years of age, achieving a BP target of 140
to <150 mm Hg as recommended by the JNC-8 panel
was associated with less beneﬁt than the previously
recommended target of <140 mm Hg (3).
Effects of Cardiorespiratory Fitness on Blood
Pressure Trajectory With Aging in a Cohort of
Healthy Men
J. Liu, et al.
BACKGROUND Although the trajectory of blood pres-
sure (BP) with aging is well known, there is a lack of data
on how cardiorespiratory ﬁtness (hereafter referred to as
ﬁtness) affects age-associated changes in BP.
OBJECTIVES The objective of the study was to inves-
tigate whether ﬁtness alters the aging-BP trajectory.
METHODS A cohort from the Aerobics Center Longi-
tudinal Study totaling 13,953 men between 20 and 90
years of age who did not have hypertension, cardio-
vascular disease, or cancer completed 3 to 28 (mean of
3.8) follow-up medical examinations between 1970
and 2006. Fitness was measured by a maximal
treadmill exercise test. Longitudinal data were
analyzed using linear mixed models.
RESULTS Diastolic blood pressure (DBP) tended to
increase until nearly 60 years of age, when a decrease
was observed. Systolic blood pressure (SBP) tended to
increase over all age periods. On multivariate analysis,
average SBP increased by 0.30 mm Hg (95% conﬁ-
dence interval: 0.29 to 0.31) with 1-year age increment
after adjusting for body fat percent, ﬁtness, resting
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703heart rate, glucose level, triglyceride level, cholesterol
level, current smoking, heavy alcohol consumption,
and parental history of hypertension. DBP had a
yearly increase of 0.14 mm Hg (95% conﬁdence
interval: 0.13 to 0.15) before age 60 years. Overall,
abnormal SBP (>120 mm Hg) began to occur at
approximately 50 years of age and abnormal DBP
(>80 mm Hg) began to occur at 60 years of age. Men
with higher ﬁtness levels experienced abnormal SBP
later than those with low ﬁtness levels.
CONCLUSIONS Our ﬁndings underscore the potential
modifying effect of ﬁtness on BP trajectory with aging
over the male adult life span. Improving ﬁtness levels
might extend the normal SBP and DBP ranges, delay-
ing the development of hypertension (4).Anatomic Assessment of Sympathetic
Peri-Arterial Renal Nerves in Man
K. Sakakura, et al.
BACKGROUND Although renal sympathetic denerva-
tion therapy has shown promising results in patients
with resistant hypertension, the human anatomy of
peri-arterial renal nerves is poorly understood.
OBJECTIVES The aim of our study was to investigate
the anatomic distribution of peri-arterial sympathetic
nerves around human renal arteries.
METHODS Bilateral renal arteries were collected
from human autopsy subjects, and peri-arterial renal
nerve anatomy was examined by using morpho-
metric software. The ratio of afferent to efferent
nerve ﬁbers was investigated by dual immuno-
ﬂuorescence staining using antibodies targeted for
anti–tyrosine hydroxylase and anti–calcitonin gene–
related peptide.
RESULTS A total of 10,329 nerves were identiﬁed from
20 (12 hypertensive and 8 nonhypertensive) patients.
The mean individual number of nerves in the proximal
and middle segments was similar (39.6  16.7 per sec-
tion and 39.9  1 3.9 per section), whereas the distal
segment showed fewer nerves (33.6  13.1 per section)
(p ¼ 0.01). Mean subject-speciﬁc nerve distance to
arterial lumen was greatest in proximal segments (3.40
 0.78 mm), followed by middle segments (3.10 
0.69 mm), and least in distal segments (2.60  0.77
mm) (p < 0.001). The mean number of nerves in the
ventral region (11.0  3.5 per section) was greater
compared with the dorsal region (6.2  3.0
per section) (p < 0.001). Efferent nerve ﬁbers were
predominant (tyrosine hydroxylase/calcitonin gene–
related peptide ratio 25.1  33.4; p < 0.0001).
Nerve anatomy in hypertensive patients was notconsiderably different compared with nonhypertensive
patients.
CONCLUSIONS The density of peri-arterial renal
sympathetic nerve ﬁbers is lower in distal segments
and dorsal locations. There is a clear predominance
of efferent nerve ﬁbers, with decreasing prevalence
of afferent nerves from proximal to distal peri-
arterial and renal parenchyma. Understanding these
anatomic patterns is important for reﬁnement of
renal denervation procedures (5).Innervation Patterns May Limit Response to
Endovascular Renal Denervation
A.R. Tzafriri, et al.
BACKGROUND Renal denervation is a new interven-
tional approach to treat hypertension with variable
results.
OBJECTIVES The purpose of this study was to corre-
late response to endovascular radiofrequency ablation
of renal arteries with nerve and ganglia distributions.
We examined how renal neural network anatomy
affected treatment efﬁcacy.
METHODS A multielectrode radiofrequency catheter
(15 W/60 s) treated 8 renal arteries (group 1).
Arteries and kidneys were harvested 7 days post-
treatment. Renal norepinephrine (NEPI) levels were
correlated with ablation zone geometries and
neural injury. Nerve and ganglion distributions and
sizes were quantiﬁed at discrete distances from the
aorta and were compared with 16 control arteries
(group 2).
RESULTS Nerve and ganglia distributions varied with
distance from the aorta (p < 0.001). A total of 75% of
nerves fell within a circumferential area of 9.3, 6.3,
and 3.4 mm of the lumen and 0.3, 3.0, and 6.0 mm
from the aorta. Efﬁcacy (NEPI 37 ng/g) was observed
in only 1 of 8 treated arteries where ablation involved
all 4 quadrants, reached a depth of 9.1 mm, and
affected 50% of nerves. In 7 treated arteries,
NEPI levels remained at baseline values (620 to 991
ng/g), #20% of the nerves were affected, and the
ablation areas were smaller (16.2  10.9 mm2) and
present in only 1 to 2 quadrants at maximal depths of
3.8  2.7 mm.
CONCLUSIONS Renal denervation procedures that
do not account for asymmetries in renal periarterial
nerve and ganglia distribution may miss targets and
fall below the critical threshold for effect. This phe-
nomenon is most acute in the ostium but holds
throughout the renal artery, which requires further
deﬁnition (6).
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Left Atrial Size and Function:
Role in Prognosis
B.D. Hoit, et al.
The author examines the ability of left atrial size and
function to predict cardiovascular outcomes. Data are
sufﬁcient to recommend evaluation of left atrial
volume in certain populations, and although analysis
of atrial reservoir, conduit, and booster pump function
trails in that regard, the gap is rapidly closing. In this
state-of-the-art paper, the author reviews the methods
used to assess left atrial size and function and
discusses their role in predicting cardiovascular events
in general and referral populations and in patients
with atrial ﬁbrillation, cardiomyopathy, ischemic heart
disease, and valvular heart disease (7).
Short-Term Rosuvastatin Therapy for Prevention
of Contrast-Induced Acute Kidney Injury in
Patients With Diabetes and Chronic
Kidney Disease
Y. Han, et al.
OBJECTIVES This study sought to evaluate the safety
and efﬁcacy of rosuvastatin in preventing contrast-
induced acute kidney injury (CI-AKI) in patients with
diabetes mellitus (DM) and chronic kidney disease (CKD).
BACKGROUND CI-AKI is an important complication
after contrast medium injection. While small studies
have shown positive results with statin therapy, the
role of statin therapy in prevention of CI-AKI remains
unknown.
METHODS We randomized 2,998 patients with type 2
DM and concomitant CKD who were undergoing coro-
nary/peripheral arterial angiography with or without
percutaneous intervention to receive rosuvastatin, 10 mg/
day (n ¼ 1,498), for 5 days (2 days before, and 3 days after
procedure) or standard-of-care (n ¼ 1,500). Patients’ renal
function was assessed at baseline, 48 h, and 72 h after
exposure to contrast medium. The primary endpoint of
the study was the development of CI-AKI, which was
deﬁned as an increase in serum creatinine concentration
$0.5 mg/dl (44.2 mmol/l) or 0.25% above baseline at 72
h after exposure to contrast medium.
RESULTS Patients randomized to the rosuvastatin
group had a signiﬁcantly lower incidence of CI-AKI
than controls (2.3% vs. 3.9%, respectively; p ¼ 0.01).
During 30 days’ follow-up, the rate of worsening
heart failure was signiﬁcantly lower in the patients
treated with rosuvastatin than that in the control
group (2.6% vs. 4.3%, respectively; p ¼ 0.02).CONCLUSIONS Rosuvastatin signiﬁcantly reduced the
risk of CI-AKI in patients with DM and CKD undergoing
arterial contrast medium injection. (Rosuvastatin
Prevent Contrast Induced Acute Kidney Injury in
Patients With Diabetes [TRACK-D]; NCT00786136) (8).
Coronary Artery Calciﬁcation: Pathogenesis and
Prognostic Implications
M.V. Madhavan, et al.
Coronary artery calciﬁcation (CAC) is a risk factor for
adverse outcomes in the general population and in
patients with coronary artery disease. The pathogenesis
of CAC and bone formation share common pathways,
and risk factors have been identiﬁed that contribute to
the initiation and progression of CAC. Efforts to control
CAC with medical therapy have not been successful.
Event-free survival is also reduced in patients with
coronary calciﬁcation after both percutaneous coronary
intervention (PCI) and bypass graft surgery. Although
drug-eluting stents and devices for plaque modiﬁcation
have modestly improved outcomes in calciﬁed vessels,
adverse event rates are still high. Innovative
pharmacologic and device-based approaches are needed
to improve the poor prognosis of patients with CAC (9).
Coronary Computed Tomography Angiography
for the Detection of Cardiac Allograft
Vasculopathy: A Meta-Analysis
of Prospective Trials
O. Wever-Pinzon, et al.
OBJECTIVES This study aimed to evaluate the diag-
nostic accuracy of coronary computed tomography
angiography (CCTA) for detecting cardiac allograft
vasculopathy (CAV) in comparison with conventional
coronary angiography (CCAG) alone or with intravas-
cular ultrasound (IVUS).
BACKGROUND CAV limits long-term survival after heart
transplantation, and screening for CAV is performed on
annual basis. CCTA is currently not recommended for
CAV screening due to the limited accuracy reported by
early studies. Technological advances, however, might
have resulted in improved test performance and might
justify re-evaluation of this recommendation.
METHODS A systematic review of Medline, Cochrane,
and Embase for all prospective trials assessing CAV using
CCTA was performed using a standard approach for
meta-analysis for diagnostic test and a bivariate analysis.
RESULTS Thirteen studies evaluating 615 patients
(mean age 52 years, 83% male) and 9,481 segments
fulﬁlled inclusion criteria. Patient-based analyses
comparing CCTA versus CCAG for the detection of any
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705CAV (> luminal irregularities) and signiﬁcant CAV
(stenosis $50%), showed mean weighted sensitivities
of 97% and 94%, speciﬁcities of 81% and 92%,
a negative predictive value (NPV) of 97% and 99%, a
positive predictive value (PPV) of 78% and 67%, and
diagnostic accuracies of 88% and 94%, respectively.
There was a strong trend toward improved sensitivity
(97% vs. 91%; p¼0.06) andNPV (99% vs. 97%; p¼0.06)
to detect signiﬁcant CAV with 64-slice compared with
16-slice CCTA. A patient-based analysis of 64-slice
CCTA versus IVUS showed a mean weighted
sensitivity and speciﬁcity of 81% and 75% to detect
CAV (intimal thickening >0.5 mm), whereas the PPV
and NPV were 93% and 50%, respectively.
CONCLUSIONS CCTA using currently available tech-
nology is a reliable noninvasive imaging alternative to
coronary angiography with an excellent sensitivity,
speciﬁcity, and NPV for the detection of CAV (10).
Cardiac Positron Emission Tomography Enhances
Prognostic Assessments of Patients With
Suspected Cardiac Sarcoidosis
R. Blankstein, et al.
OBJECTIVES This study sought to relate imaging
ﬁndings on positron emission tomography (PET) to
adverse cardiac events in patients referred for evalu-
ation of known or suspected cardiac sarcoidosis.
BACKGROUND Although cardiac PET is commonly
used to evaluate patients with suspected cardiac
sarcoidosis, the relationship between PET ﬁndings
and clinical outcomes has not been reported.
METHODS We studied 118 consecutive patients with no
history of coronary artery disease, who were referred for
PET, using [18F]ﬂuorodeoxyglucose (FDG) to assess for
inﬂammation and rubidium-82 to evaluate for perfusion
defects (PD), following a high-fat/low-carbohydrate diet
to suppress normal myocardial glucose uptake. Blind
readings of PET data categorized cardiac ﬁndings as
normal, positive PD or FDG, positive PD and FDG.
Images were also used to identify whether ﬁndings of
extra-cardiac sarcoidosis were present. Adverse events
(AE)—death or sustained ventricular tachycardia (VT)—
were ascertained by electronic medical records,
deﬁbrillator interrogation, patient questionnaires, and
telephone interviews.
RESULTS Among the 118 patients (age 52  11 years;
57% males; mean ejection fraction: 47  16%), 47
(40%) had normal and 71 (60%) had abnormal cardiac
PET ﬁndings. Over a median follow-up of 1.5 years,
there were 31 (26%) adverse events (27 VT and 8
deaths). Cardiac PET ﬁndings were predictive of AE,
and the presence of both a PD and abnormal FDG(29% of patients) was associated with hazard ratio of
3.9 (p < 0.01) and remained signiﬁcant after
adjusting for left ventricular ejection fraction (LVEF)
and clinical criteria. Extra-cardiac FDG uptake (26%
of patients) was not associated with AE.
CONCLUSIONS The presence of focal PD and FDG
uptake on cardiac PET identiﬁes patients at higher risk
of death or VT. These ﬁndings offer prognostic value
beyond Japanese Ministry of Health and Welfare
clinical criteria, the presence of extra-cardiac
sarcoidosis and LVEF (11).
Distinct Morphological Features of Ruptured
Culprit Plaque for Acute Coronary Events
Compared to Those With Silent Rupture and
Thin-Cap Fibroatheroma: A Combined Optical
Coherence Tomography and Intravascular
Ultrasound Study
J. Tian, et al.
OBJECTIVES The study sought to identify speciﬁc
morphological characteristics of ruptured culprit plaques
(RCP) responsible for acute events, and compare them
with ruptured nonculprit plaques (RNCP) and non-
ruptured thin-cap ﬁbroatheroma (TCFA) in patients
presenting with acute coronary syndromes (ACS).
BACKGROUND Nonruptured TCFA and multiple
ruptured plaques are detected in the same patients
with ACS. It remains unknown whether certain
morphological characteristics determine rupture of
TCFA and subsequently result in ACS.
METHODS We analyzed 126 plaques (RCP ¼ 49,
RNCP ¼ 19, TCFA ¼ 58) from 82 ACS patients using
optical coherence tomography (OCT) and intravas-
cular ultrasound (IVUS). Fibrous cap thickness was
determined by OCT. Plaque burden and lumen area
were measured with IVUS.
RESULTS Fibrous cap was thinner in RCP (43  11 mm)
and RNCP (41  10 mm) than in TCFA (56  9 mm;
p < 0.001 and p < 0.001, respectively). Plaque burden
was greater in RCP (82  7.2%), compared with RNCP
(64  7.2%; p < 0.001) and TCFA (62  12.5%; p < 0.001).
Lumen area was smaller in RCP (2.1  0.9 mm2),
compared with RNCP (4.6  2.3 mm2; p ¼ 0.001) and
TCFA (5.1  2.7 mm2; p < 0.001). The ﬁbrous cap thick-
ness <52 mm had good performance in discriminating
ruptured plaque from TCFA (area under the curve
[AUC] ¼ 0.857; p < 0.001), and plaque burden >76% and
lumen area <2.6 mm2 had good performance in
discriminating RCP from RNCP and TCFA (AUC ¼ 0.923,
p < 0.001; and AUC ¼ 0.881, p < 0.001, respectively).
CONCLUSIONS Fibrous cap thickness is a critical mor-
phological discriminator between ruptured plaques
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lumen area appear to be important morphological
features of RCP. These ﬁndings suggest that plaque
rupture is determined by ﬁbrous cap thickness, and
a combination of large plaque burden and luminal
narrowing result in ACS (12).
Prevalence and Characteristics of TCFA and
Degree of Coronary Artery Stenosis: An OCT,
IVUS, and Angiographic Study
J. Tian, et al.
BACKGROUND The relationship between features of
vulnerable plaque and angiographic coronary stenosis
is unknown.
OBJECTIVES The purpose of this study was to system-
atically investigate the absolute number, relative preva-
lence, and characteristics of thin-cap ﬁbroatheroma
(TCFA) at different degrees of stenosis using optical
coherence tomography (OCT), intravascular ultrasound,
and coronary angiography.
METHODS We identiﬁed 643 plaques from 255 sub-
jects who underwent OCT imaging in all 3 coronary
arteries. They were divided into 3 groups on the basis
of angiographic diameter stenosis: Group A (30% to
49%, n ¼ 325), Group B (50% to 69%, n ¼ 227), and
Group C (>70%, n ¼ 91).
RESULTS OCT showed that the absolute number of
TCFA was greatest in Group A (n ¼ 58), followed by
Groups B (n ¼ 40) and C (n ¼ 33). However, the relative
prevalence of TCFA was higher in Group C (36%) than
in Groups A (18%) or B (18%) (p ¼ 0.003 and p ¼ 0.002,
respectively). Fibrous cap of TCFA was thinner in
Group C than in Groups A (p < 0.001) or B (p ¼ 0.001).
Intravascular ultrasound showed that the plaque
burden of TCFA was largest in Group C (80.1  7.4%),
compared with Groups B (67.5  9.4%) and A (58.1 
8.4%). TCFA in Group C had a higher remodeling in-
dex than those in Group A (p ¼ 0.002).
CONCLUSIONS The absolute number of TCFA is 3
times greater in nonsevere stenosis than in severe
stenosis. It is, however, twice as likely for a lesion to
be TCFA in cases of severe stenosis than in nonsevere
stenosis. Moreover, TCFA in severely-stenotic areas
had more features of plaque vulnerability (13).
OCT Assessment of the Long-Term Vascular
Healing Response 5 Years After Everolimus-
Eluting Bioresorbable Vascular Scaffold
A. Karanasos, et al.
BACKGROUND Although recent observations suggest
a favorable initial healing process of the everolimus-eluting bioresorbable vascular scaffold (BVS), little is
known regarding long-term healing response.
OBJECTIVES This study assessed the in vivo vascular
healing response using optical coherence tomography
(OCT) 5 years after elective ﬁrst-in-man BVS
implantation.
METHODS Of the 14 living patients enrolled in
the Thoraxcenter Rotterdam cohort of the ABSORB
A study, 8 patients underwent invasive follow-up,
including OCT, 5 years after implantation. Advanced
OCT image analysis included luminal morphometry,
assessment of the adluminal signal-rich layer
separating the lumen from other plaque components,
visual and quantitative tissue characterization,
and assessment of side-branch ostia “jailed” at
baseline.
RESULTS In all patients, BVS struts were integrated in
the vessel and were not discernible. Both minimum
and mean luminal area increased from 2 to 5 years,
whereas lumen eccentricity decreased over time. In
most patients, plaques were covered by a signal-rich,
low-attenuating layer. Minimum cap thickness over
necrotic core was 155  90 mm. One patient showed
plaque progression and discontinuity of this layer.
Side-branch ostia were preserved with tissue bridge
thinning that had developed in the place of side-
branch struts, creating a neo-carina.
CONCLUSIONS At long-term BVS follow-up, we
observed a favorable tissue response, with late
luminal enlargement, side-branch patency, and
development of a signal-rich, low-attenuating tissue
layer that covered thrombogenic plaque components.
The small size of the study and the observation of a
different tissue response in 1 patient warrant judicious
interpretation of our results and conﬁrmation in larger
studies (14).METABOLIC DISORDERS & LIPIDS
Body Mass Index and Mortality in Acutely
Decompensated Heart Failure Across the World:
A Global Obesity Paradox
R. Shah, et al.
OBJECTIVES This study sought to deﬁne the rela-
tionship between body mass index (BMI) and mortal-
ity in heart failure (HF) across the world and to
identify speciﬁc groups in whom BMI may differen-
tially mediate risk.
BACKGROUND Obesity is associated with incident HF,
but it is paradoxically associated with better prognosis
during chronic HF.
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707METHODS We studied 6,142 patients with acute
decompensated HF from 12 prospective observational
cohorts followed-up across 4 continents. Primary
outcome was all-cause mortality. Cox proportional
hazards models and net reclassiﬁcation index
described associations of BMI with all-cause mortality.
RESULTS Normal-weight patients (BMI 18.5 to 25 kg/
m2) were older with more advanced HF and lower
cardiometabolic risk. Despite worldwide heterogene-
ity in clinical features across obesity categories, a
higher BMI remained associated with decreased 30-
day and 1-year mortality (11% decrease at 30 days; 9%
decrease at 1 year per 5 kg/m2; p < 0.05), after
adjustment for clinical risk. The BMI obtained at index
admission provided effective 1-year risk reclassiﬁca-
tion beyond current markers of clinical risk (net
reclassiﬁcation index 0.119; p < 0.001). Notably, the
“protective” association of BMI with mortality was
conﬁned to persons with older age (>75 years; hazard
ratio [HR]: 0.82; p ¼ 0.006), decreased cardiac func-
tion (ejection fraction <50%; HR: 0.85; p < 0.001), no
diabetes (HR: 0.86; p < 0.001), and de novo HF (HR:
0.89; p ¼ 0.004).
CONCLUSIONS A lower BMI is associated with age,
disease severity, and a higher risk of death in acute
decompensated HF. The “obesity paradox” is conﬁned
to older persons, with decreased cardiac function, less
cardiometabolic illness, and recent-onset HF, sug-
gesting that aging, HF severity/chronicity, and meta-
bolism may explain the obesity paradox (15).
Obesity and Cardiovascular Diseases:
Implications Regarding Fitness, Fatness,
and Severity in the Obesity Paradox
C.J. Lavie, et al.
Obesity has been increasing in epidemic proportions,
with a disproportionately higher increase in morbid
or class III obesity, and obesity adversely affects
cardiovascular (CV) hemodynamics, structure, and
function, as well as increases the prevalence of most
CV diseases. Progressive declines in physical activity
over 5 decades have occurred and have primarily
caused the obesity epidemic. Despite the potential
adverse impact of overweight and obesity, recent
epidemiological data have demonstrated an
association of mild obesity and, particularly,
overweight on improved survival. We review in detail
the obesity paradox in CV diseases where overweight
and at least mildly obese patients with most CV
diseases seem to have a better prognosis than do
their leaner counterparts. The implications of
cardiorespiratory ﬁtness with prognosis are discussed,along with the joint impact of ﬁtness and adiposity
on the obesity paradox. Finally, in light of the obesity
paradox, the potential value of purposeful weight loss
and increased physical activity to affect levels of
ﬁtness is reviewed (16).
Early High-Dose Rosuvastatin for Contrast-
Induced Nephropathy Prevention in Acute
Coronary Syndrome: Results From the PRATO-
ACS Study (Protective Effect of Rosuvastatin and
Antiplatelet Therapy On Contrast-Induced Acute
Kidney Injury and Myocardial Damage in Patients
With Acute Coronary Syndrome)
M. Leoncini, et al.
OBJECTIVES This study sought to determine if in
addition to standard preventive measures on-
admission, high-dose rosuvastatin exerts a protective
effect against contrast-induced acute kidney injury
(CI-AKI).
BACKGROUND Patients with acute coronary syn-
drome (ACS) are at high risk for CI-AKI, and the role of
statin pre-treatment in preventing renal damage
remains uncertain.
METHODS Consecutive statin-naïve non-ST elevation
ACS patients scheduled to undergo early invasive
strategy were randomly assigned to receive rosuvastatin
(40 mg on admission, followed by 20 mg/day; statin
group n ¼ 252) or no statin treatment (control group
n ¼ 252). CI-AKI was deﬁned as an increase in creatinine
concentration of $0.5 mg/dl or $25% above baseline
within 72 h after contrast administration.
RESULTS The incidence of CI-AKI was signiﬁcantly
lower in the statin group than in controls (6.7% vs.
15.1%; adjusted odds ratio: 0.38; 95% conﬁdence
interval [CI]: 0.20 to 0.71; p ¼ 0.003). The beneﬁts
against CI-AKI were consistent, even applying
different CI-AKI deﬁnition criteria and in all the pre-
speciﬁed risk categories. The 30-day incidence of
adverse cardiovascular and renal events (death,
dialysis, myocardial infarction, stroke, or persistent
renal damage) was signiﬁcantly lower in the statin
group (3.6% vs. 7.9%, respectively; p ¼ 0.036).
Moreover, statin treatment given on admission was
associated with a lower rate of death or nonfatal
myocardial infarction at 6 month follow-up (3.6% vs.
7.2%, respectively; p ¼ 0.07).
CONCLUSIONS High-dose rosuvastatin given on
admission to statin-naïve patients with ACS who are
scheduled for an early invasive procedure can prevent
CI-AKI and improve short-term clinical outcome.
(Statin Contrast Induced Nephropathy Prevention
[PRATO-ACS]; NCT01185938) (17).
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708Implications of the 2013 ACC/AHA Cholesterol
Guidelines for Adults in Contemporary
Cardiovascular Practice: Insights From the
NCDR PINNACLE Registry
T.M. Maddox, et al.
BACKGROUND In a signiﬁcant update, the 2013 Amer-
ican College of Cardiology/American Heart Association
(ACC/AHA) cholesterol guidelines recommend ﬁxed-
dose statin therapy for those at risk and do not recom-
mend nonstatin therapies or treatment to target
low-density lipoprotein cholesterol (LDL-C) levels,
limiting the need for repeated LDL-C testing.
OBJECTIVES The goal of this study was to examine
the impact of the 2013 ACC/AHA cholesterol guidelines
on current U.S. cardiovascular practice.
METHODS Using the NCDR PINNACLE (National Car-
diovascular Data Registry Practice Innovation and
Clinical Excellence) registry data from 2008 to 2012,
we assessed current practice patterns as a function of
the 2013 cholesterol guidelines. Lipid-lowering
therapies and LDL-C testing patterns by patient risk
group (atherosclerotic cardiovascular disease
[ASCVD], diabetes, LDL-C $190 mg/dl, or an
estimated 10-year ASCVD risk $7.5%) were described.
RESULTS Among a cohort of 1,174,545 patients,
1,129,205 (96.1%) were statin-eligible (91.2% ASCVD,
6.6% diabetes, 0.3% off-treatment LDL-C $190 mg/dl,
1.9% estimated 10-year ASCVD risk $7.5%). There were
377,311 patients (32.4%) not receiving statin therapy
and 259,143 (22.6%) receiving nonstatin therapies.
During the study period, 20.8% of patients had 2 or
more LDL-C assessments, and 7.0% had more than 4.
CONCLUSIONS In U.S. cardiovascular practices, 32.4%
of statin-eligible patients, as deﬁned by the 2013 ACC/
AHA cholesterol guidelines, were not currently
receiving statins. In addition, 22.6% were receiving
nonstatin lipid-lowering therapies and 20.8% had
repeated LDL-C testing. Achieving concordance with
the new cholesterol guidelines in patients treated in
U.S. cardiovascular practices would result in signiﬁcant
increases in statin use, as well as signiﬁcant reductions
in nonstatin therapies and laboratory testing (18).Accuracy of Statin Assignment Using the
2013 AHA/ACC Cholesterol Guideline Versus the
2001 NCEP ATP III Guideline: Correlation With
Atherosclerotic Plaque Imaging
K.M. Johnson, et al.
BACKGROUND Accurate assignment of statin therapy
is a major public health issue.OBJECTIVES The American Heart Association and the
American College of Cardiology released a new
guideline on the assessment of cardiovascular risk
(GACR) to replace the 2001 National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III rec-
ommendations. The aim of this study was to
determine which method more accurately assigns
statins to patients with features of coronary imaging
known to have predictive value for cardiovascular
events and whether more patients would be assigned
to statins under the new method.
METHODS The burden of coronary atherosclerosis on
computed tomography angiography was measured in
several ways on the basis of a 16-segment model.
Whether to assign a given patient to statin therapy
was compared between the NCEP and GACR
guidelines.
RESULTS A total of 3,076 subjects were studied
(65.3% men, mean age 55.4  10.3 years, mean age of
women 58.9  10.3 years). The probability of pre-
scribing statins rose sharply with increasing plaque
burden under the GACR compared with the NCEP
guideline. Under the NCEP guideline, 59% of patients
with $50% stenosis of the left main coronary artery
and 40% of patients with $50% stenosis of other
branches would not have been treated. The compara-
ble results for the GACR were 19% and 10%. The use of
low-density lipoprotein targets seriously degraded the
accuracy of the NCEP guideline for statin assignment.
The proportion of patients assigned to statin therapy
was 15% higher under the GACR.
CONCLUSIONS The new American Heart Association/
American College of Cardiology guideline matches
statin assignment to total plaque burden better than
the older guidelines, with only a modest increase in
the number of patients who were assigned statins (19).
The Severe Hypercholesterolemia Phenotype:
Clinical Diagnosis, Management,
and Emerging Therapies
A.D. Sniderman, et al.
The severe hypercholesterolemia phenotype includes
all patients with marked elevation of low-density
lipoprotein cholesterol (LDL-C) levels. The most com-
mon cause is autosomal dominant hypercho-
lesterolemia, an inherited disorder caused by mutations
either in LDL receptor, apolipoprotein B (APOB), or
proprotein convertase subtilisin kexin type 9 (PCSK9)
genes. However, it is now known that many subjects
with severe inherited hypercholesterolemia have no
defects in these genes. These cases are caused either by
mutations in genes yet to be identiﬁed or are
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defects. Because the clinical consequences of extreme
hypercholesterolemia are the same no matter the
cause, the focus should be on the identiﬁcation of
subjects with severe hypercholesterolemia, followed by
phenotypic screening of family members. Genetic
screening is not necessary to diagnose or initiate
treatment for the severe hypercholesterolemia pheno-
type. Management of severe hypercholesterolemia is
based on risk factor modiﬁcation and use of multiple
lipid-lowering medications. Lipoprotein apheresis is
indicated for coronary artery disease (CAD) patients
taking maximally tolerated therapy and with LDL-C
levels >200 mg/dl (>300 mg/dl if without CAD). A
microsomal triglyceride transfer protein inhibitor
and an antisense oligonucleotide against APOB have
recently been approved for use in subjects with
clinically diagnosed homozygous familial hypercho-
lesterolemia. PCSK9 inhibitors, currently in phase II
and III trials, lower LDL-C up to an additional 70% in
the setting of maximally tolerated medical therapy and
have the potential to reduce LDL-C to <70 mg/dl
in most patients. Early identiﬁcation of affected
individuals and aggressive treatment should signiﬁ-
cantly reduce the burden of cardiovascular disease in
society (20).Nonpharmacological Lipoprotein Apheresis
Reduces Arterial Inﬂammation in Familial
Hypercholesterolemia
D.F. van Wijk, et al.
BACKGROUND Patients with familial hypercholester-
olemia (FH) are characterized by elevated atherogenic
lipoprotein particles, predominantly low-density
lipoprotein cholesterol (LDL-C), which is associated
with accelerated atherogenesis and increased
cardiovascular risk.
OBJECTIVES This study used 18F-ﬂuorodeoxyglucose
positron emission tomography (18FDG-PET) to inves-
tigate whether arterial inﬂammation is higher in pa-
tients with FH and, moreover, whether lipoprotein
apheresis attenuates arterial wall inﬂammation in FH
patients.
METHODS In total, 38 subjects were recruited: 24 FH
patients and 14 normolipidemic controls. All subjects
underwent FDG-PET imaging at baseline. Twelve FH
patients who met the criteria for lipoprotein apheresis
underwent apheresis procedures followed by a second
FDG-PET imaging 3 days (range 1 to 4 days) after
apheresis. Subsequently, the target-to-background
ratio (TBR) of FDG uptake within the arterial wall was
assessed.RESULTS In FH patients, the mean arterial TBR was
higher compared with healthy controls (2.12  0.27 vs.
1.92  0.19; p ¼ 0.03). A signiﬁcant correlation was
observed between baseline arterial TBR and LDL-C
(R ¼ 0.37; p ¼ 0.03) that remained signiﬁcant after
adjusting for statin use (b ¼ 0.001; p ¼ 0.02) and
atherosclerosis risk factors (b ¼ 0.001; p ¼ 0.03).
LDL-C levels were signiﬁcantly reduced after
lipoprotein apheresis (284  118 mg/dl vs. 127  50
mg/dl; p < 0.001). There was a signiﬁcant reduction
of arterial inﬂammation after lipoprotein apheresis
(TBR: 2.05  0.31 vs. 1.91  0.33; p < 0.02).
CONCLUSIONS The arterial wall of FH patients is
characterized by increased inﬂammation, which is
markedly reduced after lipoprotein apheresis. This
lends support to a causal role of apoprotein B–con-
taining lipoproteins in arterial wall inﬂammation and
supports the concept that lipoprotein-lowering
therapies may impart anti-inﬂammatory effects by
reducing atherogenic lipoproteins (21).
Elevated Plasma PCSK9 Level Is Equally
Detrimental for Patients With Nonfamilial
Hypercholesterolemia and Heterozygous Familial
Hypercholesterolemia, Irrespective of
Low-Density Lipoprotein Receptor Defects
G. Lambert, et al.
OBJECTIVES Do elevated proprotein convertase sub-
tilisin/kexin type 9 (PCSK9) levels constitute an
even greater risk for patients who already have
reduced low-density lipoprotein receptor (LDLR)
levels, such as those with heterozygous familial
hypercholesterolemia (HeFH)?
BACKGROUND As a circulating inhibitor of LDLR,
PCSK9 is an attractive target for lowering LDL-
cholesterol (LDL-C) levels.
METHODS Circulating PCSK9 levels were measured by
enzyme-linked immunosorbent assay in nontreated
patients with HeFH carrying a D206E (n ¼ 237), V408M
(n ¼ 117), or D154N (n ¼ 38) LDLRmissense mutation and
in normolipidemic controls (n ¼ 152). Skin ﬁbroblasts
and lymphocytes were isolated from a subset of patients
and grown in 0.5% serum andmevastatin with increasing
amounts of recombinant PCSK9. LDLR abundance at
the cell surface was determined by ﬂow cytometry.
RESULTS PCSK9 reduced LDLR expression in a dose-
dependent manner in control and FH ﬁbroblasts to
similar extents, by up to 77  8% and 82  7%,
respectively. Likewise, PCSK9 reduced LDLR abun-
dance by 39  8% in nonfamilial hypercholesterolemia
(non-FH) and by 45  10% in HeFH lymphocytes,
irrespective of their LDLR mutation status. We found
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PCSK9 and LDL-C levels in controls (beta ¼ 0.22;
p ¼ 0.0003), D206E (beta ¼ 0.20; p ¼ 0.0002),
V408M (beta ¼ 0.24; p ¼ 0.0002), and D154N (beta ¼
0.25; p ¼ 0.048) patients with HeFH. The strengths
of these associations were all similar.
CONCLUSIONS Elevated PCSK9 levels are equally
detrimental for patients with HeFH or non-FH: a 100-ng/
ml increase in PCSK9 will lead to an increase in LDL-C of
0.20 to 0.25 mmol/l in controls and HeFH alike,
irrespective of their LDLR mutation. This explains why
patients with non-FH or HeFH respond equally well to
monoclonal antibodies targeting PCSK9 (22).AMG 145, a Monoclonal Antibody Against PCSK9,
Facilitates Achievement of National Cholesterol
Education Program–Adult Treatment Panel III
Low-Density Lipoprotein Cholesterol Goals
Among High-Risk Patients: An Analysis From the
LAPLACE–TIMI 57 Trial (LDL-C Assessment with
PCSK9 monoclonaL Antibody Inhibition
Combined With Statin thErapy–Thrombolysis In
Myocardial Infarction 57)
N.R. Desai, et al.
OBJECTIVES This study sought to deﬁne the ability of
AMG 145, a monoclonal antibody directed against
proprotein convertase subtilisin kexin type 9 (PCSK9),
to enable subjects at high risk for major adverse car-
diovascular events to achieve National Cholesterol
Education Program–Adult Treatment Panel III (NCEP-
ATP III) parameters for low-density lipoprotein
cholesterol (LDL-C) and other lipid goals.
BACKGROUND Many patients at high risk for adverse
cardiovascular events are unable to achieve the NCEP-
ATP III LDL-C goal of <70 mg/dl, even with high-
potency statin therapy.
METHODS In 282 subjects from the LAPLACE–TIMI 57
(LDL-C Assessment with PCSK9 monoclonaL Antibody
Inhibition Combined With Statin thErapy–Thrombol-
ysis In Myocardial Infarction 57) trial at high
risk according to NCEP-ATP III criteria, we compared
the proportion of subjects achieving the NCEP-ATP
III recommended LDL-C goal of <70 mg/dl across
treatment arms. Other outcomes included the triple
goals of LDL-C <70 mg/dl, non–high-density
lipoprotein cholesterol (HDL-C) <100 mg/dl, and
apolipoprotein B (ApoB) <80 mg/dl.
RESULTS During the dosing interval, more than 90%
of subjects in both of the top dose groups every 2
weeks and every 4 weeks attained this lipid target
over the dosing interval, with similar success rates for
the triple lipid goal.CONCLUSIONS PCSK9 inhibition with AMG 145 en-
ables high-risk patients to achieve established lipid
goals. If this therapy demonstrates efﬁcacy for
reducing cardiovascular events with a favorable
safety proﬁle in ongoing phase 3 trials, we believe it
will have major public health implications (23).
Anti-PCSK9 Antibody Effectively Lowers
Cholesterol in Patients With Statin Intolerance:
The GAUSS-2 Randomized, Placebo-Controlled
Phase 3 Clinical Trial of Evolocumab
E. Stroes, et al.
OBJECTIVES This study sought to evaluate the efﬁ-
cacy and safety of subcutaneous evolocumab
compared with oral ezetimibe in hypercholesterolemic
patients who are unable to tolerate effective statin
doses.
BACKGROUND Statin intolerance, which is predomi-
nantly due to muscle-related side effects, is reported
in up to 10% to 20% of patients. Evolocumab,
a fully human monoclonal antibody to proprotein
convertase subtilisin/kexin type 9 (PCSK9), demonstrated
marked reductions in plasma low-density lipoprotein
cholesterol (LDL-C) in a phase 2 study in statin-intolerant
patients.
METHODS The GAUSS-2 (Goal Achievement after
Utilizing an Anti-PCSK9 Antibody in Statin Intolerant
Subjects) trial was a 12-week, double-blind study of
randomized patients (2:2:1:1) to evolocumab 140 mg
every 2 weeks (Q2W) or evolocumab 420 mg once
monthly (QM) both with daily oral placebo or
subcutaneous placebo Q2W or QM both with daily
oral ezetimibe 10 mg. Co-primary endpoints were
percent change from baseline in LDL-C at the mean
of weeks 10 and 12, and at week 12.
RESULTS Three hundred seven patients (age 62  10
years; LDL-C 193  59 mg/dl) were randomized.
Evolocumab reduced LDL-C from baseline by 53% to
56%, corresponding to treatment differences versus
ezetimibe of 37% to 39% (p <0.001). Muscle adverse
events occurred in 12% of evolocumab-treated
patients and 23% of ezetimibe-treated patients.
Treatment-emergent adverse events and laboratory
abnormalities were comparable across treatment
groups.
CONCLUSIONS Robust efﬁcacy combined with favor-
able tolerability makes evolocumab a promising ther-
apy for addressing the largely unmet clinical need in
high-risk patients with elevated cholesterol who are
statin intolerant. (Goal Achievement After Utilizing
an Anti-PCSK9 Antibody in Statin Intolerant
Subjects-2; NCT01763905) (24).
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711Anti-PCSK9 Monotherapy for
Hypercholesterolemia:TheMENDEL-2Randomized,
Controlled Phase III Clinical Trial of Evolocumab
M.J. Koren, et al.
OBJECTIVES The aim of this study was to compare
biweekly and monthly evolocumab with placebo and
oral ezetimibe in patients with hypercholesterolemia
in a phase III trial.
BACKGROUND Evolocumab, a fully human mono-
clonal antibody against proprotein convertase subtil-
isin/kexin type 9 (PCSK9), signiﬁcantly reduced LDL-C
in phase II trials.
METHODS Patients 18 to 80 years of age with fasting
low-density lipoprotein cholesterol (LDL-C) $100
and <190 mg/dl and Framingham risk scores #10%
were randomized (1:1:1:1:2:2) to oral placebo and
subcutaneous (SC) placebo biweekly; oral placebo
and SC placebo monthly; ezetimibe and SC placebo
biweekly; ezetimibe and SC placebo monthly; oral
placebo and evolocumab 140 mg biweekly; or oral
placebo and evolocumab 420 mg monthly.
RESULTS A total of 614 patients were randomized and
administered doses. Evolocumab treatment reduced
LDL-C from baseline, on average, by 55% to 57% more
than placebo and 38% to 40% more than
ezetimibe (p < 0.001 for all comparisons). Evolocumab
treatment also favorably altered other lipoprotein
levels. Treatment-emergent adverse events (AEs),
muscle-related AEs, and laboratory abnormalities were
comparable across treatment groups.
CONCLUSIONS In the largest monotherapy trial using
a PCSK9 inhibitor to date, evolocumab yielded sig-
niﬁcant LDL-C reductions compared with placebo or
ezetimibe and was well tolerated in patients with
hypercholesterolemia. (Monoclonal Antibody Against
PCSK9 to Reduce Elevated LDL-C in Subjects
Currently Not Receiving Drug Therapy for Easing
Lipid Levels-2 [MENDEL-2]; NCT01763827) (25).
Lipoprotein(a) for Risk Assessment in Patients
With Established Coronary Artery Disease
M.L. O’Donoghue, et al.
OBJECTIVES The purpose of this study was to assess
the prognostic utility of lipoprotein(a) [Lp(a)] in in-
dividuals with coronary artery disease (CAD).
BACKGROUND Data regarding an association between
Lp(a) and cardiovascular (CV) risk in secondary pre-
vention populations are sparse.
METHODS Plasma Lp(a) was measured in 6,708 sub-
jects with CAD from 3 studies; data were thencombined with 8 previously published studies for a
total of 18,978 subjects.
RESULTS Across the 3 studies, increasing levels of
Lp(a) were not associated with the risk of CV events
when modeled as a continuous variable (odds ratio
[OR]: 1.03 per log-transformed SD, 95% conﬁdence
interval [CI]: 0.96 to 1.11) or by quintile (Q5:Q1 OR:
1.05, 95% CI: 0.83 to 1.34). When data were
combined with previously published studies of Lp(a)
in secondary prevention, subjects with Lp(a) levels
in the highest quantile were at increased risk of
CV events (OR: 1.40, 95% CI: 1.15 to 1.71), but with
signiﬁcant between-study heterogeneity (p ¼ 0.001).
When stratiﬁed on the basis of low-density
lipoprotein (LDL) cholesterol, the association between
Lp(a) and CV events was signiﬁcant in studies in
which average LDL cholesterol was $130 mg/dl (OR:
1.46, 95% CI: 1.23 to 1.73; p < 0.001), whereas this
relationship did not achieve statistical signiﬁcance for
studies with an average LDL cholesterol <130 mg/dl
(OR: 1.20, 95% CI: 0.90 to 1.60; p ¼ 0.21).
CONCLUSIONS Lp(a) is signiﬁcantly associated with the
risk of CV events in patients with established CAD;
however, there exists marked heterogeneity across trials.
In particular, the prognostic value of Lp(a) in patients
with low cholesterol levels remains unclear (26).
Lipoprotein(a) Levels in Familial
Hypercholesterolemia: An Important Predictor of
Cardiovascular Disease Independent of the Type
of LDL Receptor Mutation
R. Alonso, et al.
OBJECTIVES The aim of this study was to determine
the relationship between lipoprotein(a) [Lp(a)] and
cardiovascular disease (CVD) in a large cohort of pa-
tients with heterozygous familial hypercholesterole-
mia (FH).
BACKGROUND Lp(a) is considered a cardiovascular
risk factor. Nevertheless, the role of Lp(a) as a pre-
dictor of CVD in patients with FH has been a contro-
versial issue.
METHODS A cross-sectional analysis of 1,960 pa-
tients with FH and 957 non-FH relatives recruited
for SAFEHEART (Spanish Familial Hypercholester-
olemia Cohort Study), a long-term observational
cohort study of a molecularly well-deﬁned FH study
group, was performed. Lp(a) concentrations were
measured in plasma using an immunoturbidimetric
method.
RESULTS Patients with FH, especially those with
CVD, had higher Lp(a) plasma levels compared with
their unaffected relatives (p < 0.001). A signiﬁcant
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frequent null and defective mutations in LDLR muta-
tions were analyzed (p < 0.0016). On multivariate
analysis, Lp(a) was an independent predictor of car-
diovascular disease. Patients carrying null mutations
and Lp(a) levels >50 mg/dl showed the highest car-
diovascular risk compared with patients carrying the
same mutations and Lp(a) levels <50 mg/dl.
CONCLUSIONS Lp(a) is an independent predictor of
CVD in men and women with FH. The risk of CVD is
higher in those patients with an Lp(a) level >50 mg/dl
and carrying a receptor-negative mutation in the LDLR
gene compared with other less severe mutations (27).
Reduction in Lipoprotein(a) With PCSK9
Monoclonal Antibody Evolocumab (AMG 145):
A Pooled Analysis of More Than 1,300 Patients
in 4 Phase II Trials
F.J. Raal, et al.
OBJECTIVES The purpose of this study was assess the
effect of evolocumab (AMG 145) on lipoprotein (Lp)(a)
from a pooled analysis of 4 phase II trials.
BACKGROUND Lp(a), a low-density lipoprotein (LDL)
particle linked to the plasminogen-like glycoprotein
apolipoprotein(a), shows a consistent and inde-
pendent positive association with cardiovascular
disease risk in epidemiological studies. Current
therapeutic options to reduce Lp(a) are limited.
METHODS A pooled analysis of data from 1,359 pa-
tients in 4 phase II trials assessed the effects of evo-
locumab, a fully human monoclonal antibody to
PCSK9, on Lp(a), the relationship between Lp(a) and
lowering of low-density lipoprotein cholesterol (LDL-
C) and apolipoprotein B, and the inﬂuence of
background statin therapy. Lp(a) was measured
using a standardized isoform-independent method.
RESULTS Evolocumab treatment for 12weeks resulted in
signiﬁcant (p < 0.001) mean (95% conﬁdence interval)
dose-related reductions in Lp(a) compared to control:
29.5% (23.3% to 35.7%) and 24.5% (20.4% to 28.7%) with
140 mg and 420 mg, dosed every 2 and 4 weeks,
respectively, with no plateau of effect. Lp(a) reductions
were signiﬁcantly correlated with percentages of
reductions in LDL-C (Spearman correlation coefﬁcient,
0.5134; p < 0.001) and apolipoprotein B (Spearman
correlation coefﬁcient, 0.5203; p < 0. 001). Mean per-
centage reductions did not differ based on age or sex
but the trend was greater in those patients taking statins.
CONCLUSIONS Inhibition of PCSK9 with evolocumab
resulted in signiﬁcant dose-related reductions in Lp(a).
While the mean percentage of reduction was
signiﬁcantly greater in those patients with baselineLp(a) of #125 nmol/l, the absolute reduction was
substantially larger in those with levels >125 nmol/l (28).
Genetics and Causality of Triglyceride-Rich
Lipoproteins in Atherosclerotic Cardiovascular
Disease
R.S. Rosenson, et al.
Triglycerides represent 1 component of a heterogeneous
pool of triglyceride-rich lipoproteins (TGRLs). The
reliance on triglycerides or TGRLs as cardiovascular
disease (CVD) risk biomarkers prompted investigations
into therapies that lower plasma triglycerides as a means
to reduce CVD events. Genetic studies identiﬁed TGRL
components and pathways involved in their synthesis
and metabolism. We advocate that only a subset of
genetic mechanisms regulating TGRLs contribute to the
risk of CVD events. This “omic” approach recently
resulted in new targets for reducing CVD events (29).NEUROVASCULAR & NEURODEGENERATIVE
DISORDERS
Atrial Autonomic Innervation: A Target for
Interventional Antiarrhythmic Therapy?
D. Linz, et al.
Atrial ﬁbrillation is the most common arrhythmia and is
associated with signiﬁcant morbidity and mortality. The
autonomic nervous system contributes to the creation
of atrial ﬁbrillation substrates. Atrial electrophysiology
is inﬂuenced differently by sympathetic and para-
sympathetic activation. Several strategies are available
to modulate the complex interaction between the
autonomic nervous system and the heart. However,
different approaches target the problem differently
making the prediction of arrhythmogenic and/or
antiarrhythmic effects difﬁcult. We discuss the role of
the autonomic nervous system on the development of
a substrate for atrial ﬁbrillation and explore the
potential antiarrhythmic and/or arrhythmogenic effect
of modulation of the autonomic nervous system by
renal sympathetic denervation, ganglionated plexi
ablation, ganglion stellatum ablation, high thoracic
epidural anesthesia, low-level vagal nerve stimulation,
and baroreﬂex stimulation (30).
Regional Myocardial Sympathetic Denervation
Predicts the Risk of Sudden Cardiac Arrest in
Ischemic Cardiomyopathy
J.A. Fallavollita, et al.
OBJECTIVES The PAREPET (Prediction of ARrhythmic
Events with Positron Emission Tomography) study
J A C C V O L . 6 5 , N O . 7 , 2 0 1 5 Fuster
F E B R U A R Y 2 4 , 2 0 1 5 : 7 0 1 – 3 7 Highlights of the Year
713sought to test the hypothesis that quantifying in-
homogeneity in myocardial sympathetic innervation
could identify patients at highest risk for sudden car-
diac arrest (SCA).
BACKGROUND Left ventricular ejection fraction
(LVEF) is the only parameter identifying patients at
risk of SCA who beneﬁt from an implantable cardiac
deﬁbrillator (ICD).
METHODS We prospectively enrolled 204 subjects
with ischemic cardiomyopathy (LVEF #35%) eligible
for primary prevention ICDs. Positron emission to-
mography (PET) was used to quantify myocardial
sympathetic denervation (11C-meta-hydroxyephedrine
[11C-HED]), perfusion (13N-ammonia) and viability
(insulin-stimulated 18F-2-deoxyglucose). The primary
endpoint was SCA deﬁned as arrhythmic death or
ICD discharge for ventricular ﬁbrillation or
ventricular tachycardia >240 beats/min.
RESULTS After 4.1 years follow-up, cause-speciﬁc SCA
was 16.2%. Infarct volume (22  7% vs. 19  9% of left
ventricle [LV]) and LVEF (24  8% vs. 28  9%) were
not predictors of SCA. In contrast, patients developing
SCA had greater amounts of sympathetic denervation
(33  10% vs. 26  11% of LV; p ¼ 0.001) reﬂecting
viable, denervated myocardium. The lower tertiles of
sympathetic denervation had SCA rates of 1.2%/year
and 2.2%/year, whereas the highest tertile had a rate of
6.7%/year. Multivariate predictors of SCA were PET
sympathetic denervation, left ventricular end-diastolic
volume index, creatinine, and no angiotensin
inhibition. With optimized cut-points, the absence of
all 4 risk factors identiﬁed low risk (44% of cohort;
SCA <1%/year); whereas $2 factors identiﬁed high risk
(20% of cohort; SCA w12%/year).
CONCLUSIONS In ischemic cardiomyopathy, sympa-
thetic denervation assessed using 11C-HED PET pre-
dicts cause-speciﬁc mortality from SCA independently
of LVEF and infarct volume. This may provide an
improved approach for the identiﬁcation of patients
most likely to beneﬁt from an ICD. (Prediction
of ARrhythmic Events With Positron Emission
Tomography [PAREPET]; NCT01400334) (31).A Molecular Mechanism for Adrenergic-Induced
Long QT Syndrome
J. Wu, et al.
OBJECTIVES This study sought to explore molecular
mechanisms underlying the adrenergic-induced QT
prolongation associated with KCNQ1 mutations.
BACKGROUND The most frequent type of congenital
long QT syndrome is LQT1, which is caused bymutations in the gene (KCNQ1) that encodes the alpha
subunit of the slow component of delayed rectiﬁer Kþ
current (IKs) channel. We identiﬁed 11 patients from 4
unrelated families that are heterozygous for KCNQ1-
G269S. Most patients remained asymptomatic, and
their resting corrected QT intervals ranged from
normal to borderline but were prolonged signiﬁcantly
during exercise.
METHODS Wild-type (WT) KCNQ1 and/or KCNQ1-
G269S (G269S)were expressed inmammalian cells with
KCNE1. IKs-like currents were measured in control
conditions or after isoproterenol or protein kinase A
(PKA) stimulation using the patch-clamp technique.
Additionally, experiments that incorporated the
phosphomimetic KCNQ1 substitution, S27D, in WT or
KCNQ1-G269S were also performed.
RESULTS The coexpression of WT-KCNQ1 with vary-
ing amounts of G269S decreased IKs, shifted the
current-voltage I-V relation of IKs to more positive
potentials, and accelerated the IKs deactivation rates
in a concentration-dependent manner. In addition,
the coexpression of G269S and WT blunted the
activation of IKs in response to isoproterenol or PKA
stimulation. Lastly, a phosphomimetic substitution
in G269S did not show an increased IKs.
CONCLUSIONS G269S modestly affected IKs in control
conditions, but it almost completely blunted IKs
responsiveness in conditions that simulate or mimic
PKA phosphorylation of KCNQ1. This insensitivity to
PKA stimulation may explain why patients with G269S
mutation showed an excessive prolongation of QT
intervals on exercise (32).Engineered Electrical Conduction Tract Restores
Conduction in Complete Heart Block: From
In Vitro to In Vivo Proof of Concept
E. Cingolani, et al.
BACKGROUND Cardiac electrical conduction delays
and blocks cause rhythm disturbances such as com-
plete heart block, which can be fatal. Standard of care
relies on electronic devices to artiﬁcially restore syn-
chrony. We sought to create a new modality for
treating these disorders by engineering electrical
conduction tracts designed to propagate electrical
impulses.
OBJECTIVES This study sought to create a new
approach for treating cardiac conduction disorders by
using engineered electrical conduction tracts (EECTs).
METHODS Paramagnetic beads were conjugated with
an antibody to gamma-sarcoglycan, a cardiomyocyte
cell surface antigen, and mixed with freshly isolated
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ﬁeld was used to pattern a linear EECT.
RESULTS In an in vitro model of conduction block,
the EECT was patterned so that it connected 2 inde-
pendently beating neonatal rat ventricular car-
diomyocyte monolayers; it achieved coordinated
electrical activity, with action potentials propagating
from 1 region to the other via EECT. Spiking the EECT
with heart-derived stromal cells yielded stable
structures with highly reproducible conduction
velocities. Transplantation of EECTs in vivo restored
atrioventricular conduction in a rat model of
complete heart block.
CONCLUSIONS An EECT can re-establish electrical
conduction in the heart. This novel approach could,
in principle, be used not only to treat cardiac
arrhythmias but also to repair other organs (33).RHYTHM DISORDERS
Aggressive Risk Factor Reduction Study for Atrial
Fibrillation and Implications for the Outcome of
Ablation: The ARREST-AF Cohort Study
R.K. Pathak, et al.
BACKGROUND The long-term outcome of atrial
ﬁbrillation (AF) ablation demonstrates attrition. This
outcome may be due to failure to attenuate the
progressive substrate promoted by cardiovascular
risk factors.
OBJECTIVES The goal of this study was to evaluate
the impact of risk factor and weight management on
AF ablation outcomes.
METHODS Of 281 consecutive patients undergoing AF
ablation, 149 with a body mass index $27 kg/m2
and $1 cardiac risk factor were offered risk factor
management (RFM) according to American Heart As-
sociation/American College of Cardiology guidelines.
After AF ablation, all 61 patients who opted for RFM
and 88 control subjects were assessed every 3 to 6
months by clinic review and 7-day Holter monitoring.
Changes in the Atrial Fibrillation Severity Scale scores
were determined.
RESULTS There were no differences in baseline char-
acteristics, number of procedures, or follow-up
duration between the groups (p ¼ NS). RFM resulted
in greater reductions in weight (p ¼ 0.002) and blood
pressure (p ¼ 0.006), and better glycemic control
(p ¼ 0.001) and lipid proﬁles (p ¼ 0.01). At follow-
up, AF frequency, duration, symptoms, and
symptom severity decreased more in the RFM group
compared with the control group (all p < 0.001).Single-procedure drug-unassisted arrhythmia-free
survival was greater in RFM patients compared with
control subjects (p < 0.001). Multiple-procedure
arrhythmia-free survival was markedly better in RFM
patients compared with control subjects (p < 0.001),
with 16% and 42.4%, respectively, using anti-
arrhythmic drugs (p ¼ 0.004). On multivariate
analysis, type of AF (p < 0.001) and RFM (hazard
ratio 4.8 [95% conﬁdence interval: 2.04 to 11.4];
p < 0.001) were independent predictors of arrhythmia-
free survival.
CONCLUSIONS Aggressive RFM improved the long-
term success of AF ablation. This study underscores
the importance of therapy directed at the primary
promoters of the AF substrate to facilitate rhythm
control strategies (34).Atrial Remodeling and Atrial Fibrillation:
Recent Advances and Translational Perspectives
S. Nattel, et al.
Atrial ﬁbrillation (AF) is the most common sustained
arrhythmia in clinical practice. AF and its complications
are responsible for important population morbidity and
mortality. Presently available therapeutic approaches
have limited efﬁcacy and nontrivial potential to cause
adverse effects. Thus, new mechanistic knowledge
is essential for therapeutic innovation. Atrial
arrhythmogenic remodeling, deﬁned as any change in
atrial structure or function that promotes atrial
arrhythmias, is central to AF. Remodeling can be due
to underlying cardiac conditions, systemic processes
and conditions such as aging, or AF itself. Recent work
has underlined the importance of remodeling in AF,
provided new insights into basic mechanisms, and
identiﬁed new biomarker/imaging approaches to follow
remodeling processes. The importance of intracellular
Ca2þ handling abnormalities has been highlighted, both
for the induction of triggered ectopic activity and for
the activation of Ca2þ-related cell signaling that
mediates proﬁbrillatory remodeling. The importance of
microRNAs, which are a new class of small noncoding
sequences that regulate gene expression, has emerged
in both electrical and structural remodeling.
Remodeling related to aging, cardiac disease, and AF
itself is believed to underlie the progressive nature of
the arrhythmia, which contributes to the complexities
of long-term management. New tools that are being
developed to quantify remodeling processes and
monitor their progression include novel biomarkers,
imaging modalities to quantify/localize ﬁbrosis, and
noninvasive monitoring/mapping to better characterize
the burden of AF and identify arrhythmic sources. This
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715report reviews recent advances in the understanding of
the basic pathophysiology of atrial remodeling and
potential therapeutic implications (35).
Lone Atrial Fibrillation: Does it Exist?
D.G. Wyse, et al.
The historical origin of the term “lone atrial
ﬁbrillation” (AF) predates by 60 years our current
understanding of the pathophysiology of AF, the
multitude of known etiologies for AF, and our ability
to image and diagnose heart disease. The term was
meant to indicate AF in patients for whom
subsequent investigations could not demonstrate
heart disease, but for many practitioners has become
synonymous with “idiopathic AF.” As the list of heart
diseases has expanded and diagnostic techniques
have improved, the prevalence of lone AF has fallen.
The legacy of the intervening years is that deﬁnitions
of lone AF in the literature are inconsistent so that
studies of lone AF are not comparable. Guidelines
provide a vague deﬁnition of lone AF but do not
provide direction about how much or what kind of
imaging and other testing are necessary to exclude
heart disease. There has been an explosion in the
understanding of the pathophysiology of AF in the
last 20 years in particular. Nevertheless, there are no
apparently unique mechanisms for AF in patients
categorized as having lone AF. In addition, the term
“lone AF” is not invariably useful in making
treatment decisions, and other tools for doing so have
been more thoroughly and carefully validated. It is,
therefore, recommended that use of the term “lone
AF” be avoided (36).
Alcohol Consumption and Risk of Atrial
Fibrillation: A Prospective Study and
Dose-Response Meta-Analysis
S.C. Larsson, et al.
BACKGROUND Although high alcohol consumption
has been associated with increased risk of atrial
ﬁbrillation (AF), the role of light to moderate drinking
remains unclear.
OBJECTIVES The study sought to investigate the as-
sociation between alcohol consumption and AF risk in
a prospective study of Swedish men and women and
to conduct a meta-analysis of prospective studies to
summarize available evidence.
METHODS We followed 79,019 men and women who,
at baseline, were free from AF and had completed a
questionnaire about alcohol consumption and other
risk factors for chronic diseases. Incident AF caseswere ascertained by linkage to the Swedish Inpatient
Register. For the meta-analysis, studies were
identiﬁed by searching PubMed through January 10,
2014, and by reviewing references of pertinent
publications. Study-speciﬁc relative risks (RRs) were
combined using a random effects model.
RESULTS Over 859,420 person-years of follow-up
(1998 to 2009), 7,245 incident AF cases were
identiﬁed in our own cohort study. The association
between alcohol consumption and AF did not differ
by sex (p for interaction ¼ 0.74). Compared with
current drinkers of <1 drink/week (12 g alcohol/
drink), the multivariable RRs of AF were 1.01 (95%
conﬁdence interval [CI]: 0.94 to 1.09) for 1 to 6
drinks/week, 1.07 (95% CI: 0.98 to 1.17) for 7 to 14
drinks/week, 1.14 (95% CI: 1.01 to 1.28) for 15 to 21
drinks/week, and 1.39 (95% CI: 1.22 to 1.58) for >21
drinks/week. Results were similar after excluding
binge drinkers. In a meta-analysis of 7 prospective
studies, including 12,554 AF cases, the RRs were 1.08
(95% CI: 1.06 to 1.10) for 1 drink/day, 1.17 (95% CI:
1.13 to 1.21) for 2 drinks/day, 1.26 (95% CI: 1.19 to
1.33) for 3 drinks/day, 1.36 (95% CI: 1.27 to 1.46) for 4
drinks/day, and 1.47 (95% CI: 1.34 to 1.61) for 5
drinks/day, compared with nondrinkers.
CONCLUSIONS These ﬁndings indicate that alcohol
consumption, even at moderate intakes, is a risk factor
for atrial ﬁbrillation (37).
Insights Into Onco-Cardiology:
Atrial Fibrillation in Cancer
D. Farmakis, et al.
Atrial ﬁbrillation (AF) has been found to occur with an
increased frequency in patients with malignancies,
particularly in those undergoing cancer surgery. The
occurrence of AF in cancer may be related to comorbid
states or a direct tumor effect or may represent a
complication of cancer surgical or medical therapy,
whereas inﬂammation may be a common denominator
for both conditions. Treating AF in patients with
malignancies is a challenge, especially in terms of
antithrombotic therapy, because cancer may result in an
increased risk of either thrombosis or hemorrhage and
an unpredictable anticoagulation response, whereas
thromboembolic risk prediction scores such as CHADS2
(Cardiac Failure, Hypertension, Age, Diabetes, and
Stroke [doubled]) may not be applicable. The general
lack of evidence imposes an individualized approach to
the management of AF in those patients, although some
general recommendations based on current guidelines
in noncancer patients and the existing evidence in
cancer patients, where available, may be outlined (38).
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716Increased Mortality Associated With Digoxin in
Contemporary Patients With Atrial Fibrillation:
Findings From the TREAT-AF Study
M.P. Turakhia, et al.
BACKGROUND Despite endorsement of digoxin in
clinical practice guidelines, there exist limited data on
its safety in atrial ﬁbrillation/ﬂutter (AF).
OBJECTIVES The goal of this study was to evaluate
the association of digoxin with mortality in AF.
METHODS Using complete data of the TREAT-AF
(The Retrospective Evaluation and Assessment of
Therapies in AF) study from the U.S. Department of
Veterans Affairs (VA) healthcare system, we identiﬁed
patients with newly diagnosed, nonvalvular AF seen
within 90 days in an outpatient setting between VA
ﬁscal years 2004 and 2008. We used multivariate and
propensity-matched Cox proportional hazards to
evaluate the association of digoxin use with death.
Residual confounding was assessed by sensitivity
analysis.
RESULTS Of 122,465 patients with 353,168 person-years
of follow-up (age 72.1  10.3 years, 98.4% male), 28,679
(23.4%) patients received digoxin. Cumulative mortality
rates were higher for digoxin-treated patients than for
untreated patients (95 vs. 67 per 1,000 person-years;
p < 0.001). Digoxin use was independently associated
with mortality after multivariate adjustment (hazard
ratio [HR]: 1.26, 95% conﬁdence interval [CI]: 1.23 to
1.29; p < 0.001) and propensity matching (HR: 1.21, 95%
CI: 1.17 to 1.25; p < 0.001), even after adjustment for
drug adherence. The risk of death was not modiﬁed by
age, sex, heart failure, kidney function, or concomitant
use of beta-blockers, amiodarone, or warfarin.
CONCLUSIONS Digoxin was associated with increased
risk of death in patients with newly diagnosed AF,
independent of drug adherence, kidney function,
cardiovascular comorbidities, and concomitant thera-
pies. These ﬁndings challenge current cardiovascular
society recommendations on use of digoxin in AF (39).Clinical Classiﬁcations of Atrial Fibrillation Poorly
Reﬂect Its Temporal Persistence: Insights From
1,195 Patients Continuously Monitored With
Implantable Devices
E.I. Charitos, et al.
OBJECTIVES This study aimed to identify how accu-
rately the current clinical atrial ﬁbrillation (AF) clas-
siﬁcations reﬂect its temporal persistence.
BACKGROUND Clinical classiﬁcation of AF is
employed to communicate its persistence, to selectappropriate therapies, and as inclusion criterion for
clinical trials.
METHODS Cardiac rhythm histories of 1,195 patients
(age 73.0  10.1 years, follow-up: 349  40 days) with
implantable devices were reconstructed and analyzed.
Patients were classiﬁed as having paroxysmal or
persistent AF by physicians at baseline in accordance
with current guidelines. AF burden, measured as the
proportion of time spent in AF, was obtained from the
device. Additionally we evaluated the agreement
between clinical and device-derived AF classiﬁcations.
RESULTS Patients within the same clinical class were
highly heterogeneous with regards to AF temporal
persistence. Agreement between the clinical AF clas-
siﬁcationand theobjectivedevice-derivedassessmentsof
AF temporal persistence was poor (Cohen’s kappa: 0.12
[95% CI: 0.05 to 0.18]). Patient characteristics inﬂuenced
the clinical decision to classify AF as paroxysmal or
persistent. Higher ejection fraction (odds ratio: 0.97/per
unit [95% CI: 0.95 to 0.98/per unit]; p < 0.0001) and
presence of coronary artery disease (odds ratio: 0.53
[95% CI: 0.32 to 0.88]; p ¼ 0.01) were independently
associated with a lower probability of being classiﬁed as
persistent AF for the same AF burden level.
CONCLUSIONS The currently used clinical AF classi-
ﬁcations poorly reﬂect AF temporal persistence. Pa-
tient characteristics signiﬁcantly inﬂuence the
physician’s classiﬁcation of AF. Patients classiﬁed in
identical clinical categories may be inherently het-
erogeneous with regard to AF temporal persistence.
Further study is required to determine if patient
selection on the basis of objective criteria derived
from rigorous AF monitoring can improve reported
outcomes and better identify responders and non-
responders to treatments. (OMNI Study–Assessing
Therapies in Medtronic Pacemaker, Deﬁbrillator,
and Cardiac Resynchronization Therapy Devices;
NCT00277524; TRENDS: A Prospective Study of the
Clinical Signiﬁcance of Atrial Arrhythmias Detected
by Implanted Device Diagnostics; NCT00279981) (40).Amiodarone, Anticoagulation, and Clinical Events
in Patients With Atrial Fibrillation: Insights From
the ARISTOTLE Trial
G. Flaker, et al.
BACKGROUND Amiodarone is an effective medication
in preventing atrial ﬁbrillation (AF), but it interferes
with the metabolism of warfarin.
OBJECTIVES This study sought to examine the asso-
ciation of major thrombotic clinical events and bleed-
ing with the use of amiodarone in the ARISTOTLE
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boembolic Events in Atrial Fibrillation) trial.
METHODS Baseline characteristics of patients who
received amiodarone at randomization were
compared with those who did not receive amiodarone.
The interaction between randomized treatment and
amiodarone was tested using a Cox model, with main
effects for randomized treatment and amiodarone and
their interaction. Matching on the basis of a pro-
pensity score was used to compare patients who
received and who did not receive amiodarone at the
time of randomization.
RESULTS In ARISTOTLE, 2,051 (11.4%) patients received
amiodarone at randomization. Patients on warfarin and
amiodarone had time in the therapeutic range that was
lower than patients not on amiodarone (56.5% vs. 63.0%;
p < 0.0001). More amiodarone-treated patients had a
stroke or a systemic embolism (1.58%/year vs. 1.19%/
year; adjusted hazard ratio [HR]: 1.47, 95% conﬁdence
interval [CI]: 1.03 to 2.10; p ¼ 0.0322). Overall mortality
and major bleeding rates were elevated, but were not
signiﬁcantly different in amiodarone-treated patients
and patients not on amiodarone. When comparing
apixaban with warfarin, patients who received
amiodarone had a stroke or a systemic embolism rate
of 1.24%/year versus 1.85%/year (HR: 0.68, 95% CI:
0.40 to 1.15), death of 4.15%/year versus 5.65%/year
(HR: 0.74, 95% CI: 0.55 to 0.98), and major bleeding of
1.86%/year versus 3.06%/year (HR: 0.61, 95% CI: 0.39
to 0.96). In patients who did not receive amiodarone,
the stroke or systemic embolism rate was 1.29%/year
versus 1.57%/year (HR: 0.82, 95% CI: 0.68 to 1.00),
death was 3.43%/year versus 3.68%/year (HR: 0.93,
95% CI: 0.83 to 1.05), and major bleeding was 2.18%/
year versus 3.03%/year (HR: 0.72, 95% CI: 0.62 to 0.84).
The interaction p values for amiodarone use by
apixaban treatment effects were not signiﬁcant.
CONCLUSIONS Amiodarone use was associated with
signiﬁcantly increased stroke and systemic embolism
risk and a lower time in the therapeutic range when used
with warfarin. Apixaban consistently reduced the rate of
stroke and systemic embolism, death, and major
bleeding compared with warfarin in amiodarone-treated
patients and patients who were not on amiodarone (41).
Net Clinical Beneﬁt of Antithrombotic Therapy in
Patients With Atrial Fibrillation and Chronic
Kidney Disease: A Nationwide Observational
Cohort Study
A.N. Bonde, et al.
BACKGROUND The balance between stroke reduction
and increased bleeding associated with antithrombotictherapy among patients with atrial ﬁbrillation (AF) and
chronic kidney disease (CKD) is controversial.
OBJECTIVES This study assessed the risk associated
with CKD in individual CHA2DS2-VASc (Congestive
heart failure; Hypertension; Age $75 years; Diabetes
mellitus; previous Stroke, transient ischemic attack, or
thromboembolism; Vascular disease; Age 65 to 74
years; Sex category) strata and the net clinical beneﬁt
of warfarin in patients with AF and CKD in a nation-
wide cohort.
METHODS By individual-level linkage of nationwide
Danish registries, we identiﬁed all patients discharged
with nonvalvular AF from 1997 to 2011. The stroke
risk associated with non-end-stage CKD and end-stage
CKD (e.g., patients on renal replacement therapy
[RRT]) was estimated using Cox regression analyses.
The net clinical beneﬁt of warfarin was assessed
using 4 endpoints: a composite endpoint of death/
hospitalization from stroke/bleeding; a composite
endpoint of fatal stroke/fatal bleeding; cardiovascular
death; and all-cause death.
RESULTS From nonvalvular AF patients (n ¼ 154,259),
we identiﬁed 11,128 patients (7.2%) with non-end-stage
CKD and 1,728 (1.1%) receiving RRT. In all CHA2DS2-
VASc risk groups, RRT was independently associated
with a higher risk of stroke/thromboembolism, from a
5.5-fold higher risk in patients with CHA2DS2-VASc
score ¼ 0 to a 1.6-fold higher risk in patients with
CHA2DS2-VASc score $2. In patients receiving RRT
with CHA2DS2-VASc score $2, warfarin was associated
with lower risk of all-cause death (hazard ratio [HR]:
0.85, 95% conﬁdence interval [CI]: 0.72 to 0.99). In
non-end-stage CKD patients with CHA2DS2-VASc
score $2, warfarin was associated with a lower risk of
a composite outcome of fatal stroke/fatal bleeding
(HR: 0.71, 95% CI: 0.57 to 0.88), a lower risk of
cardiovascular death (HR: 0.80, 95% CI: 0.74 to 0.88),
and a lower risk of all-cause death (HR: 0.64, 95% CI:
0.60 to 0.69).
CONCLUSIONS CKD is associated with a higher risk of
stroke/thromboembolism across stroke risk strata in
AF patients. High-risk CKD patients (CHA2DS2-
VASc $2) with AF beneﬁt from warfarin treatment
for stroke prevention (42).Triple Therapy for Atrial Fibrillation and
Percutaneous Coronary Intervention:
A Contemporary Review
W.J.M. Dewilde, et al.
Chronic oral anticoagulant therapy is recommended
(class I) in patients with mechanical heart valves and in
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(Congestive heart failure, Hypertension, Age $75 years,
Diabetes mellitus, prior Stroke or transient ischemic
attack or thromboembolism, Vascular disease, Age 65 to
74 years, Sex category) score $1. When these patients
undergo percutaneous coronary intervention with
stenting, treatment with aspirin and a P2Y12 receptor
inhibitor also becomes indicated. Before 2014,
guidelines recommended the use of triple therapy
(vitamin K antagonists, aspirin, and clopidogrel) for
these patients. However, major bleeding is increasingly
recognized as the Achilles’ heel of the triple therapy
regimen. Lately, various studies have investigated this
topic, including a prospective randomized trial, and the
evidence for adding aspirin to the regimen of vitamin K
antagonists and clopidogrel seems to be weakened. In
this group of patients, the challenge is ﬁnding the
optimal equilibrium to prevent thromboembolic events,
such as stent thrombosis and thromboembolic stroke,
without increasing bleeding risk (43).The Effect of Dabigatran Plasma Concentrations
and Patient Characteristics on the Frequency of
Ischemic Stroke and Major Bleeding in Atrial
Fibrillation Patients: The RE-LY Trial
(Randomized Evaluation of Long-Term
Anticoagulation Therapy)
P.A. Reilly, et al.
OBJECTIVES The goal of this study was to analyze the
impact of dabigatran plasma concentrations, patient
demographics, and aspirin (ASA) use on frequencies of
ischemic strokes/systemic emboli and major bleeds in
atrial ﬁbrillation patients.
BACKGROUND The efﬁcacy and safety of dabigatran
etexilate were demonstrated in the RE-LY (Randomized
Evaluation of Long-Term Anticoagulation Therapy)
trial, but a therapeutic concentration range has not
been deﬁned.
METHODS In a pre-speciﬁed analysis of RE-LY, plasma
concentrations of dabigatran were determined in
patients treated with dabigatran etexilate 110 mg twice
daily (bid) or 150 mg bid and correlated with the
clinical outcomes of ischemic stroke/systemic embolism
and major bleeding using univariate and multivariate
logistic regression and Cox regression models. Patient
demographics and ASA use were assessed descriptively
and as covariates.
RESULTS Plasma concentrations were obtained from
9,183 patients, with 112 ischemic strokes/systemic
emboli (1.3%) and 323 major bleeds (3.8%) recorded.
Dabigatran levels were dependent on renal function,
age, weight, and female sex, but not ethnicity,geographic region, ASA use, or clopidogrel use. A
multiple logistic regression model (c-statistic 0.657,
95% conﬁdence interval [CI]: 0.61 to 0.71) showed that
the risk of ischemic events was inversely related to
trough dabigatran concentrations (p ¼ 0.045), with
age and previous stroke (both p < 0.0001) as signiﬁ-
cant covariates. Multiple logistic regression (c-statistic
0.715, 95% CI: 0.69 to 0.74) showed major bleeding
risk increased with dabigatran exposure (p < 0.0001),
age (p < 0.0001), ASA use (p < 0.0003), and diabetes
(p ¼ 0.018) as signiﬁcant covariates.
CONCLUSIONS Ischemic stroke and bleeding out-
comes were correlated with dabigatran plasma con-
centrations. Age was the most important covariate.
Individual beneﬁt–risk might be improved by tailoring
dabigatran dose after considering selected patient
characteristics. (Randomized Evaluation of Long Term
Anticoagulant Therapy [RE-LY] With Dabigatran
Etexilate; NCT00262600) (44).
Factors Associated With Major Bleeding Events:
Insights From the ROCKET AF Trial (Rivaroxaban
Once-daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in
Atrial Fibrillation)
S.G. Goodman, et al.
OBJECTIVES This study sought to report additional
safety results from the ROCKET AF (Rivaroxaban
Once-daily oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke
and Embolism Trial in Atrial Fibrillation).
BACKGROUND The ROCKET AF trial demonstrated
similar risks of stroke/systemic embolism and major/
nonmajor clinically relevant bleeding (principal safety
endpoint) with rivaroxaban and warfarin.
METHODS The risk of the principal safety and compo-
nent bleeding endpoints with rivaroxaban versus
warfarin were compared, and factors associated with
major bleeding were examined in a multivariable model.
RESULTS The principal safety endpoint was similar in
the rivaroxaban and warfarin groups (14.9 vs. 14.5
events/100 patient-years; hazard ratio: 1.03; 95%
conﬁdence interval: 0.96 to 1.11). Major bleeding risk
increased with age, but there were no differences
between treatments in each age category (<65, 65 to
74, $75 years; pinteraction ¼ 0.59). Compared with those
without (n ¼ 13,455), patients with a major bleed
(n ¼ 781) were more likely to be older, current/prior
smokers, have prior gastrointestinal (GI) bleeding, mild
anemia, and a lower calculated creatinine clearance and
less likely to be female or have a prior stroke/transient
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pressure (DBP) $90 mm Hg, history of chronic
obstructive pulmonary disease or GI bleeding, prior
acetylsalicylic acid use, and anemia were indepen-
dently associated with major bleeding risk; female sex
and DBP <90 mm Hg were associated with a decreased
risk.
CONCLUSIONS Rivaroxaban and warfarin had similar
risk for major/nonmajor clinically relevant bleeding.
Age, sex, DBP, prior GI bleeding, prior acetylsalicylic
acid use, and anemia were associated with the risk of
major bleeding. (An Efﬁcacy and Safety Study of
Rivaroxaban With Warfarin for the Prevention of
Stroke and Non-Central Nervous System Systemic
Embolism in Patients With Non-Valvular Atrial
Fibrillation; NCT00403767) (45).
Feasibility and Safety of Uninterrupted
Rivaroxaban for Periprocedural Anticoagulation
in Patients Undergoing Radiofrequency Ablation
for Atrial Fibrillation: Results From a Multicenter
Prospective Registry
D. Lakkireddy, et al.
OBJECTIVES The purpose of this study was to eval-
uate the feasibility and safety of uninterrupted rivar-
oxaban therapy during atrial ﬁbrillation (AF) ablation.
BACKGROUND Optimal periprocedural anticoagulation
strategy is essential for minimizing bleeding and throm-
boembolic complicationsduringandafterAFablation.The
safety and efﬁcacy of uninterrupted rivaroxaban therapy
as a periprocedural anticoagulant for AF ablation are
unknown.
METHODS We performed a multicenter, observa-
tional, prospective study of a registry of patients un-
dergoing AF ablation in 8 centers in North America.
Patients taking uninterrupted periprocedural rivarox-
aban were matched by age, sex, and type of AF with an
equal number of patients taking uninterrupted
warfarin therapy who were undergoing AF ablation
during the same period.
RESULTS A total of 642 patients were included in
the study, with 321 in each group. Mean age was 63
 10 years, with 442 (69%) males and 328 (51%)
patients with paroxysmal AF equally distributed be-
tween the 2 groups. Patients in the warfarin group
had a slightly higher mean HAS- BLED (hyperten-
sion, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile international
normalized ratio, elderly, drugs/alcohol concomi-
tantly) score (1.70  1.0 vs. 1.47  0.9, respectively;
p ¼ 0.032). Bleeding and embolic complications
occurred in 47 (7.3%) and 2 (0.3%) patients (both hadtransient ischemic attacks) respectively. There were
no differences in the number of major bleeding
complications (5 [1.6%] vs. 7 [1.9%], respectively;
p ¼ 0.772), minor bleeding complications (16 [5.0%]
vs. 19 [5.9%], respectively; p ¼ 0.602), or embolic
complications (1 [0.3%] vs. 1 [0.3%], respectively;
p ¼ 1.0) between the rivaroxaban and warfarin
groups in the ﬁrst 30 days.
CONCLUSIONS Uninterrupted rivaroxaban therapy ap-
pears to be as safe and efﬁcacious in preventing bleeding
and thromboembolic events in patients undergoing AF
ablation as uninterrupted warfarin therapy (46).Efﬁcacy and Safety of Apixaban in Patients After
Cardioversion for Atrial Fibrillation: Insights From
the ARISTOTLE Trial (Apixaban for Reduction in
Stroke and Other Thromboembolic Events in
Atrial Fibrillation)
G. Flaker, et al.
OBJECTIVES The aim of this study was to determine
the risk of major clinical and thromboembolic events
after cardioversion for atrial ﬁbrillation in subjects
treated with apixaban, an oral factor Xa inhibitor,
compared with warfarin.
BACKGROUND In patients with atrial ﬁbrillation,
thromboembolic events may occur after cardiover-
sion. This risk is lowered with vitamin K antagonists
and dabigatran.
METHODS Using data from the ARISTOTLE (Apixaban
for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation) trial, we conducted a post-
hoc analysis of patients undergoing cardioversion.
RESULTS A total of 743 cardioversions were performed
in 540 patients: 265 ﬁrst cardioversions in patients
assigned to apixaban and 275 in those assigned to
warfarin. The mean time to the ﬁrst cardioversion for
patients assigned to warfarin and apixaban was 243  231
days and 251  248 days, respectively; 75% of the car-
dioversions occurred by 1 year. Baseline characteristics
were similar between groups. In patients undergoing
cardioversion, no stroke or systemic emboli occurred in
the 30-day follow-up period. Myocardial infarction
occurred in 1 patient (0.2%) receiving warfarin and 1
patient receiving apixaban (0.3%). Major bleeding
occurred in 1 patient (0.2%) receiving warfarin and 1
patient receiving apixaban (0.3%). Death occurred in 2
patients (0.5%) receiving warfarin and 2 patients
receiving apixaban (0.6%).
CONCLUSIONS Major cardiovascular events after
cardioversion of atrial ﬁbrillation are rare and com-
parable between warfarin and apixaban. (Apixaban
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720for Reduction in Stroke and Other Thromboem-
bolic Events in Atrial Fibrillation [ARISTOTLE];
NCT00412984) (47).
Major Bleeding in Patients With Atrial Fibrillation
Receiving Apixaban or Warfarin: The ARISTOTLE
Trial (Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation):
Predictors, Characteristics, and
Clinical Outcomes
E.M. Hylek, et al.
OBJECTIVES This study sought to characterize major
bleeding on the basis of the components of the major
bleeding deﬁnition, to explore major bleeding by loca-
tion, to deﬁne 30-day mortality after a major bleeding
event, and to identify factors associated with major
bleeding.
BACKGROUND Apixaban was shown to reduce the
risk of major hemorrhage among patients with atrial
ﬁbrillation in the ARISTOTLE (Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial
Fibrillation) trial.
METHODS All patients who received at least 1 dose of
a study drug were included. Major bleeding was
deﬁned according to the criteria of the International
Society on Thrombosis and Haemostasis. Factors
associated with major hemorrhage were identiﬁed
using a multivariable Cox model.
RESULTS The on-treatment safety population included
18,140 patients. The rate of major hemorrhage among
patients in the apixaban group was 2.13% per year
compared with 3.09% per year in the warfarin group
(hazard ratio [HR] 0.69, 95% conﬁdence interval
[CI]: 0.60 to 0.80; p < 0.001). Compared with warfarin,
major extracranial hemorrhage associated with
apixaban led to reduced hospitalization, medical or
surgical intervention, transfusion, or change in
antithrombotic therapy. Major hemorrhage followed by
mortality within 30 days occurred half as often in
apixaban-treated patients than in those receiving
warfarin (HR 0.50, 95% CI: 0.33 to 0.74; p < 0.001).
Older age, prior hemorrhage, prior stroke or transient
ischemic attack, diabetes, lower creatinine clearance,
decreased hematocrit, aspirin therapy, and nonsteroidal
anti-inﬂammatory drugs were independently associated
with an increased risk.
CONCLUSIONS Apixaban, compared with warfarin,
was associated with fewer intracranial hemorrhages,
less adverse consequences following extra-
cranial hemorrhage, and a 50% reduction in fatal
consequences at 30 days in cases of major hemor-
rhage (48).Atrial Fibrillation Ablation: Translating Basic
Mechanistic Insights to the Patient
K. Nishida, et al.
Atrial ﬁbrillation (AF) ablation is widely performed and is
progressively supplanting drug therapy. Catheter-based
AF ablation modalities have evolved progressively
in parallel to our understanding of underlying
mechanisms. Initial attempts to mimic the surgical maze
procedure, which were based on the multiple wavelet
model, failed because of adverse outcomes and
insufﬁcient effectiveness. A major advance was the
targeting of pulmonary veins, which is highly effective
for paroxysmal AF. Active research on the underlying
mechanisms continues. The main challenge is
reconnection, but procedures to minimize this are being
developed. Ablation procedures for persistent AF are
presently limited by suboptimal success rates and long-
term disease progression that causes recurrences. Basic
research into the underlying mechanisms has led
to promising driver mechanism-directed clinical
approaches along with pathways toward the prevention
of atrial remodeling. Here, we review the role of basic
research in the development of presently used
AF-ablation procedures and look toward future
contributions in improving outcomes (49).
Ablation of Rotor and Focal Sources Reduces
Late Recurrence of Atrial Fibrillation Compared
With Trigger Ablation Alone: Extended Follow-
Up of the CONFIRM Trial (Conventional Ablation
for Atrial Fibrillation With or Without Focal
Impulse and Rotor Modulation)
S.M. Narayan, et al.
OBJECTIVES The aim of this study was to determine
if ablation that targets patient-speciﬁc atrial
ﬁbrillation (AF)–sustaining substrates (rotors or focal
sources) is more durable than trigger ablation alone
at preventing late AF recurrence.
BACKGROUND Late recurrence substantially limits
the efﬁcacy of pulmonary vein isolation for AF and is
associated with pulmonary vein reconnection and the
emergence of new triggers.
METHODS Three-year follow-up was performed of the
CONFIRM (Conventional Ablation for Atrial
Fibrillation With or Without Focal Impulse and Rotor
Modulation) trial, in which 92 consecutive patients
with AF (70.7% persistent) underwent novel
computational mapping. Ablation comprised source
(focal impulse and rotor modulation [FIRM]) and
then conventional ablation in 27 patients (FIRM
guided) and conventional ablation alone in 65
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implanted electrocardiographic monitors when
possible (85.2% of FIRM-guided patients, 23.1% of
FIRM-blinded patients).
RESULTS FIRM mapping revealed a median of 2
(interquartile range: 1 to 2) rotors or focal sources in
97.7% of patients during AF. During a median follow-
up period of 890 days (interquartile range: 224 to
1,563 days), compared to FIRM-blinded therapy,
patients receiving FIRM-guided ablation maintained
higher freedom from AF after 1.2  0.4 procedures
(median 1; interquartile range: 1 to 1) (77.8% vs.
38.5%; p ¼ 0.001) and a single procedure (p < 0.001)
and higher freedom from all atrial arrhythmias (p ¼
0.003). Freedom from AF was higher when ablation
directly or coincidentally passed through sources
than when it missed sources (p < 0.001).
CONCLUSIONS FIRM-guided ablation is more durable
than conventional trigger-based ablation in preventing 3-
year AF recurrence. Future studies should investigate
how ablation of patient-speciﬁc AF-sustaining rotors
and focal sources alters the natural history of
arrhythmia recurrence. (The Dynamics of Human Atrial
Fibrillation; NCT01008722) (50).Incidence of and Risk Factors for Sick Sinus
Syndrome in the General Population
P.N. Jensen, et al.
BACKGROUND Little is known about the incidence of
and risk factors for sick sinus syndrome (SSS), a com-
mon indication for pacemaker implantation.
OBJECTIVES This study sought to describe the
epidemiology of SSS.
METHODS This analysis included 20,572 participants
(mean baseline age 59 years, 43% male) in the ARIC
(Atherosclerosis Risk In Communities) study and the
CHS (Cardiovascular Health Study), who at baseline
were free of prevalent atrial ﬁbrillation and pace-
maker therapy, had a heart rate of $50 beats/min
unless using beta blockers, and were identiﬁed as of
white or black race. Incident SSS cases were identi-
ﬁed by hospital discharge International Classiﬁcation
of Disease-revision 9-Clinical Modiﬁcation code
427.81 and validated by medical record review.
RESULTS During an average 17 years of follow-up, 291
incident SSS cases were identiﬁed (unadjusted rate
0.8 per 1,000 person-years). Incidence increased
with age (hazard ratio [HR]: 1.73; 95% conﬁdence
interval [CI]: 1.47 to 2.05 per 5-year increment), and
blacks had a 41% lower risk of SSS than whites (HR:
0.59; 95% CI: 0.37 to 0.98). Incident SSS wasassociated with greater baseline body mass index,
height, N-terminal pro–B-type natriuretic peptide,
and cystatin C, with longer QRS interval, with lower
heart rate, and with prevalent hypertension, right
bundle branch block, and cardiovascular disease. We
project that the annual number of new SSS cases in
the United States will increase from 78,000 in 2012
to 172,000 in 2060.
CONCLUSIONS Blacks have a lower risk of SSS than
whites, and several cardiovascular risk factors were
associated with incident SSS. With the aging of the
population, the number of Americans with SSS will
increase dramatically over the next 50 years (51).Incidence and Causes of Sudden Death in
U.S. College Athletes
B.J. Maron, et al.
OBJECTIVES The goal of this study was to reliably
deﬁne the incidence and causes of sudden death in
college student-athletes.
BACKGROUND The frequencywithwhich cardiovascular-
related sudden death occurs in competitive athletes
importantly inﬂuences considerations for pre-participation
screening strategies.
METHODS We assessed databases (including autopsy
reports) from both the U.S. National Registry of Sud-
den Death in Athletes and the National Collegiate
Athletic Association (2002 to 2011).
RESULTS Over the 10-year study period, 182 sudden
deaths occurred (age 20  1.7 years; 85% male; 64%
white), 52 resulting from suicide (n ¼ 31) or drug abuse
(n ¼ 21) and 64 probably or likely attributable to car-
diovascular causes (6/year). Of these 64 athletes, 47
had a conﬁrmed post-mortem diagnosis; the most
common were hypertrophic cardiomyopathy in 21 and
congenital coronary anomalies in 8. The 4,052,369
athlete participations (in 30 sports over 10 years)
incurred mortality risks as follows: suicide and drugs
combined, 1.3/100,000 athlete participation-years (5
deaths/year); and documented cardiovascular disease,
1.2/100,000 athlete participation-years (4 deaths/
year). Notably, cardiovascular deaths were 5-fold
more common in African-American athletes than in
white athletes (3.8 vs. 0.7/100,000 athlete participa-
tion-years; p < 0.01) but did not differ from the gen-
eral population of the same age and race (p ¼ 0.6).
CONCLUSIONS In college student-athletes, risk of
sudden death due to cardiovascular disease is relatively
low, with mortality rates similar to suicide and drug
abuse, but less than expected in the general
population, although highest in African-American
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cardiovascular deaths would not likely have been
reliably detected by pre-participation screening with
12-lead electrocardiograms (52).
Sudden Cardiac Death Risk Stratiﬁcation in
Patients With Nonischemic Dilated
Cardiomyopathy
J.J. Goldberger, et al.
OBJECTIVES The purpose of this study was to provide
a meta-analysis to estimate the performance of 12
commonly reported risk stratiﬁcation tests as
predictors of arrhythmic events in patients with
nonischemic dilated cardiomyopathy.
BACKGROUND Multiple techniques have been
assessed as predictors of death due to ventricular
tachyarrhythmias/sudden death in patients with
nonischemic dilated cardiomyopathy.
METHODS Forty-ﬁve studies enrolling 6,088 patients
evaluating the association between arrhythmic events
and predictive tests (baroreﬂex sensitivity, heart rate
turbulence, heart rate variability, left ventricular end-
diastolic dimension, left ventricular ejection fraction,
electrophysiology study, nonsustained ventricular
tachycardia, left bundle branch block, signal-
averaged electrocardiogram, fragmented QRS, QRS-T
angle, and T-wave alternans) were included. Raw
event rates were extracted, and meta-analysis was
performed using mixed effects methodology. We also
used the trim-and-ﬁll method to estimate the
inﬂuence of missing studies on the results.
RESULTS Patients were 52.8  14.5 years of age, and
77% were male. Left ventricular ejection fraction was
30.6  11.4%. Test sensitivities ranged from 28.8% to
91.0%, speciﬁcities from 36.2% to 87.1%, and odds
ratios from 1.5 to 6.7. Odds ratio was highest for
fragmented QRS and TWA (odds ratios: 6.73 and 4.66,
95% conﬁdence intervals: 3.85 to 11.76 and 2.55 to
8.53, respectively) and lowest for QRS duration (odds
ratio: 1.51, 95% conﬁdence interval: 1.13 to 2.01). None
of the autonomic tests (heart rate variability, heart
rate turbulence, baroreﬂex sensitivity) were signiﬁ-
cant predictors of arrhythmic outcomes. Accounting
for publication bias reduced the odds ratios for the
various predictors but did not eliminate the predictive
association.
CONCLUSIONS Techniques incorporating functional
parameters, depolarization abnormalities, repolariza-
tion abnormalities, and arrhythmic markers provide
only modest risk stratiﬁcation for sudden cardiac
death in patients with nonischemic dilated cardio-
myopathy. It is likely that combinations of tests willbe required to optimize risk stratiﬁcation in this pop-
ulation (53).
Ventricular Arrhythmias in the North American
Multidisciplinary Study of ARVC: Predictors,
Characteristics, and Treatment
M.S. Link, et al.
BACKGROUND Arrhythmogenic right ventricular car-
diomyopathy (ARVC) is associated with sudden car-
diac death. However, the selection of patients for
implanted cardioverter-deﬁbrillators (ICDs), as well as
programming of the ICD, is unclear.
OBJECTIVES The objective of this study was to iden-
tify predictors, characteristics, and treatment of ven-
tricular arrhythmias in patients with ARVC.
METHODS The Multidisciplinary Study of Right
Ventricular Cardiomyopathy established the North
American ARVC Registry and enrolled patients
with a diagnosis of ARVC. Patients were followed
prospectively.
RESULTS Of 137 patients enrolled, 108 received ICDs.
Forty-eight patients had 502 sustained episodes of
ventricular arrhythmias, including 489 that were
monomorphic and 13 that were polymorphic. In the
patients with ICDs, independent predictors of
ventricular arrhythmias in follow-up included spon-
taneous sustained ventricular arrhythmias before ICD
implantation and T-wave inversions inferiorly. The
only independent predictor for life-threatening
arrhythmias, deﬁned as sustained ventricular tachy-
cardia (VT) $240 beats/min or ventricular ﬁbrillation,
was a younger age at enrollment. Anti-tachycardia
pacing (ATP), independent of the cycle length of the
VT, was successful in terminating 92% of VT episodes.
CONCLUSIONS In the North American ARVC Registry,
the majority of ventricular arrhythmias in follow-up are
monomorphic. Risk factors for ventricular arrhythmias
were spontaneous ventricular arrhythmias before
enrollment and a younger age at ICD implantation. ATP
is highly successful in terminating VT, and all ICDs
should be programmed for ATP, even for rapid VT (54).
Clinical Effectiveness of CRT and ICD Therapy
in Heart Failure Patients by Racial/Ethnic
Classiﬁcation: Insights From the IMPROVE
HF Registry
B. Ziaeian, et al.
BACKGROUND Clinical trials have demonstrated
beneﬁt for cardiac resynchronization therapy (CRT)
and implantable cardioverter-deﬁbrillator (ICD)
therapies in patients with heart failure with reduced
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723ejection fraction (HFrEF); yet, questions have been
raised with regard to the beneﬁt of device therapy
for minorities.
OBJECTIVES The purpose of this study was to deter-
mine the clinical effectiveness of CRT and ICD thera-
pies as a function of race/ethnicity in outpatients with
HFrEF (ejection fraction #35%).
METHODS Data from IMPROVE HF (Registry to
Improve the Use of Evidence-Based Heart Failure
Therapies in the Outpatient Setting) were analyzed
by device status and race/ethnicity among guideline-
eligible patients for mortality at 24 months.
Multivariate Generalized Estimating Equations
analyses were conducted, adjusting for patient and
practice characteristics.
RESULTS The ICD/cardiac resynchronization deﬁbril-
lator (CRT-D)–eligible cohort (n ¼ 7,748) included
3,391 (44%) non-Hispanic white, 719 (9%) non-
Hispanic black, and 3,638 (47%) other racial/ethnic
minorities or race-not-documented patients. The
cardiac resynchronization pacemaker (CRT-P)/CRT-
D–eligible cohort (n ¼ 1,188) included 596 (50%)
non-Hispanic white, 99 (8%) non-Hispanic black,
and 493 (41%) other/not-documented patients. There
was clinical beneﬁt associated with ICD/CRT-D
therapy (adjusted odds ratio: 0.64, 95% conﬁdence
interval: 0.52 to 0.79; p ¼ 0.0002 for 24-month
mortality), which was of similar proportion in white,
black, and other minority/not-documented patients
(device–race/ethnicity interaction p ¼ 0.7861). For
CRT-P/CRT-D therapy, there were also associated
mortality beneﬁts (adjusted odds ratio: 0.55, 95%
conﬁdence interval: 0.33 to 0.91; p ¼ 0.0222), and
the device–race/ethnicity interaction was not
signiﬁcant (p ¼ 0.5413).
CONCLUSIONS The use of guideline-directed CRT and
ICD therapy was associated with reduced 24-month
mortality without signiﬁcant interaction by racial/
ethnic group. Device therapies should be offered to
eligible heart failure patients, without modiﬁcation
based on race/ethnicity (55).The Subcutaneous Deﬁbrillator:
A Review of the Literature
S. Aziz, et al.
The recently commercially available subcutaneous
implantable cardioverter-deﬁbrillator (S-ICD) uses a
completely subcutaneous electrode conﬁguration to
treat potentially lethal ventricular tachyarrhythmia.
Clinical trials have proven its effectiveness in
detecting and treating ventricular ﬁbrillation andtachycardia. The S-ICD offers the advantage of
eliminating the need for intravenous and intracardiac
leads and their associated risks and shortcomings.
However, its major disadvantage is its inability to
provide bradycardia rate support and antitachycardia
pacing to terminate ventricular tachycardia. This
paper discusses the S-ICD clinical trials and advantages
and disadvantages of this novel technology to help the
physician identify its role and select candidate patients
who will beneﬁt from this device (56).
Rotor Stability Separates Sustained Ventricular
Fibrillation From Self-Terminating Episodes
in Humans
D.E. Krummen, et al.
OBJECTIVES This study mapped human ventricular
ﬁbrillation (VF) to deﬁne mechanistic differences be-
tween episodes requiring deﬁbrillation versus those
that spontaneously terminate.
BACKGROUND VF is a leading cause of mortality; yet,
episodes may also self-terminate. We hypothesized
that the initial maintenance of human VF is
dependent upon the formation and stability of VF
rotors.
METHODS We enrolled 26 consecutive patients (age
64  10 years, n ¼ 13 with left ventricular dysfunction)
during ablation procedures for ventricular arrhyth-
mias, using 64-electrode basket catheters in both
ventricles to map VF prior to prompt deﬁbrillation
per the institutional review board–approved
protocol. A total of 52 inductions were attempted,
and 36 VF episodes were observed. Phase analysis
was applied to identify biventricular rotors in the
ﬁrst 10 s or until VF terminated, whichever came
ﬁrst (11.4  2.9 s to deﬁbrillator charging).
RESULTS Rotors were present in 16 of 19 patients
with VF and in all patients with sustained VF.
Sustained, but not self-limiting VF, was characterized
by greater rotor stability: 1) rotors were present in
68  17% of cycles in sustained VF versus 11 
18% of cycles in self-limiting VF (p < 0.001); and 2)
maximum continuous rotations were greater in
sustained (17  11, range 7 to 48) versus self-limiting
VF (1.1  1.4, range 0 to 4; p < 0.001). Additionally,
biventricular rotor locations in sustained VF were
conserved across multiple inductions (7 of 7
patients; p ¼ 0.025).
CONCLUSIONS In patients with and without struc-
tural heart disease, the formation of stable rotors
identiﬁes individuals whose VF requires deﬁb-
rillation from those in whom VF spontaneously
self-terminates. Future work should deﬁne the
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whether rotor modulation may reduce subsequent
VF risk (57).
Electrocardiographic Parameters and Fatal
Arrhythmic Events in Patients With Brugada
Syndrome: Combination of Depolarization and
Repolarization Abnormalities
K. Tokioka, et al.
OBJECTIVES This study aimed to determine the use-
fulness of the combination of several electrocardio-
graphic markers on risk assessment of ventricular
ﬁbrillation (VF) in patients with Brugada syndrome
(BrS).
BACKGROUND Detection of high-/low-risk BrS pa-
tients using a noninvasive method is an important
issue in the clinical setting. Several electrocardio-
graphic markers related to depolarization and repo-
larization abnormalities have been reported, but the
relationship and usefulness of these parameters in VF
events are unclear.
METHODS Baseline characteristics of 246 consecutive
patients (236 men; mean age, 47.6  13.6 years) with a
Brugada-type electrocardiogram, including 13 patients
with a history of VF and 40 patients with a history of
syncope episodes, were retrospectively analyzed.
During the mean follow-up period of 45.1 months,
VF in 23 patients and sudden cardiac death (SCD) in
1 patient were observed. Clinical/genetic and
electrocardiographic parameters were compared with
VF/SCD events.
RESULTS On univariate analysis, a history of VF and
syncope episodes, paroxysmal atrial ﬁbrillation,
spontaneous type 1 pattern in the precordial leads,
and electrocardiographic markers of depolarization
abnormalities (QRS duration $120 ms, and fragmented
QRS [f-QRS]) and those of repolarization abnormalities
(inferolateral early repolarization [ER] pattern and QT
prolongation) were associated with later cardiac
events. On multivariable analysis, a history of VF
and syncope episodes, inferolateral ER pattern, and
f-QRS were independent predictors of documented
VF and SCD (odds ratios: 19.61, 28.57, 2.87, and 5.21,
respectively; p < 0.05). Kaplan-Meier curves showed
that the presence/absence of inferolateral ER and f-
QRS predicted a worse/better prognosis (log-rank
test, p < 0.01).
CONCLUSIONS The combination of depolarization
and repolarization abnormalities in BrS is associated
with later VF events. The combination of these ab-
normalities is useful for detecting high- and low-risk
BrS patients (58).Drug-Induced Brugada Syndrome in Children:
Clinical Features, Device-Based Management,
and Long-Term Follow-Up
G. Conte, et al.
OBJECTIVES The goal of this study was to investigate
the clinical features, management, and long-term
follow-up of children with drug-induced Brugada
syndrome (BS).
BACKGROUND Patients with BS <12 years of age with
a spontaneous type I electrocardiogram have a higher
risk of arrhythmic events. Data on drug-induced BS in
patients <12 years of age are lacking.
METHODS Among 505 patients with ajmaline-induced
BS, subjects #12 years of age at the time of diagnosis
were considered as children and eligible for this study.
RESULTS Forty children (60% male; age 8  2.8 years)
were included. Twenty-four children (60%) had a family
history of sudden death. Two (5%) had a previous
episode of aborted sudden death, and 8 (20%) had
syncope. Children experienced more frequent episodes
of sinus node dysfunction (SND) compared with older
subjects (7.5% vs. 1.5%; p ¼ 0.04) and had a comparable
incidence of atrial tachyarrhythmias. Children more
frequently experienced episodes of ajmaline-induced
sustained ventricular arrhythmias (VAs) compared with
older patients (10.0% vs. 1.3%; p ¼ 0.005). Twelve
children (30%) received an implantable cardioverter-
deﬁbrillator (ICD). After a mean follow-up time of 83 
51 months, none of the children died suddenly.
Spontaneous sustained VAs were documented in 1 child
(2%). Among children with ICD, 1 (8%) experienced an
appropriate shock, 4 (33%) had inappropriate ICD shocks,
and 4 (33%) experienced device-related complications.
CONCLUSIONS Drug-induced BS is associated with
atrial arrhythmias and SND. Children are at higher risk
of ajmaline-induced VAs. The rate of device-related
complications, leading to lead replacement or
inappropriate shocks, is considerable and even higher
than with appropriate interventions. Based on these
ﬁndings, the optimal management of BS in childhood
should remain individualized, taking into consideration
the patient’s clinical history and family’s wishes (59).VALVULAR HEART DISEASE
The Year in Valvular Heart Disease
S.H. Rahimtoola, et al.
A. European Society of Cardiology and the European
Association for Cardio-Thoracic Surgery. Comment: A
total of 46 pages and 241 references. Of the 66
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725recommendations, none had Level of Evidence: A.
There were 28 Class I recommendations with Level of
Evidence: B in 6 and C in 22. There were 31 Class IIa
recommendations with Level of Evidence: B in 1 and C
in 30. There are 7 Class IIb recommendations; all were
with Level of Evidence: C (60).
B-Type Natriuretic Peptide Clinical Activation in
Aortic Stenosis: Impact on Long-Term Survival
M.-A. Clavel, et al.
OBJECTIVES This study was conducted to deﬁne the
association between serum B-type natriuretic peptide
(BNP) activation and survival after the diagnosis of
aortic stenosis (AS).
BACKGROUND In AS, the link between BNP levels and
clinical outcome is in dispute. Failure to account for
the normal shifting of BNP ranges with aging in men
and women, not using hard endpoints (survival), and
not enrolling large series of patients have contributed
to the uncertainty.
METHODS A program of prospective measurement of
BNP levels with Doppler echocardiographic AS
assessment during the same episode of care was con-
ducted. BNP ratio (measured BNP/maximal normal
BNP value speciﬁc to age and sex) >1 deﬁned BNP
clinical activation.
RESULTS In 1,953 consecutive patients with at least
moderate AS (aortic valve area 1.03  0.26 cm2; mean
gradient 36  19 mm Hg), median BNP level was 252
pg/ml (interquartile range: 98 to 592 pg/ml); BNP ratio
2.46 (interquartile range 1.03 to 5.66); ejection fraction
(EF) 57%  15%, and symptoms present in 60% of
patients. After adjustment for all survival de-
terminants, BNP clinical activation (BNP ratio >1)
independently predicted mortality after diagnosis
(p < 0.0001; hazard ratio [HR]: 1.91; 95% CI: 1.55 to
2.35) and provided incremental power to the survival
predictive model (p < 0.0001). Eight-year survival was
62  3% with normal BNP levels, 44  3% with BNP
ratio of 1 to 2 (adjusted HR: 1.49; 95% CI: 1.17 to
1.90), 25  4% with BNP ratio of 2 to 3 (adjusted HR:
2.12; 95% CI: 1.63 to 2.75), and 15  2% with BNP
ratio of $3 (adjusted HR: 2.43; 95% CI: 1.94 to 3.05).
This strong link to survival was conﬁrmed in
asymptomatic patients with normal EF (adjusted HR:
2.35 [95% CI: 1.57 to 3.56] for BNP clinical activation
and 2.10 [95% CI: 1.32 to 3.36] for BNP ratio of 1 to 2,
2.25 [95% CI: 1.31 to 3.87] for BNP ratio of 2 to 3, 3.93
[95% CI: 2.40 to 6.43] for BNP ratio of $3). Aortic
valve replacement was associated with survival
improved by a similarly high margin (p ¼ 0.54) with
BNP ratio of <2 (HR: 0.68; 95% CI: 0.52 to 0.89;p ¼ 0.003) or BNP ratio of >2 (HR: 0.56; 95% CI: 0.47
to 0.66; p < 0.0001).
CONCLUSIONS In this large series of patients with AS,
BNP clinical activation was associated with excess
long-term mortality incrementally and independently
of all baseline characteristics. Higher mortality with
higher BNP clinical activation, even in asymptomatic
patients, emphasizes the importance of appropriate
clinical interpretation of BNP levels in managing
patients with AS (61).Early Surgery Versus Conventional Treatment for
Asymptomatic Severe Mitral Regurgitation:
A Propensity Analysis
D.-H. Kang, et al.
OBJECTIVES This study sought to compare long-term
outcomes of early surgery with a conventional
treatment strategy in asymptomatic patients with
severe mitral regurgitation (MR).
BACKGROUND The timing of surgery in asymptomatic
severe MR remains controversial.
METHODS From 1996 to 2009, 610 consecutive
asymptomatic patients (364 men, 50  14 years of age)
with severe degenerative MR and preserved left ven-
tricular function were evaluated prospectively. Early
surgery was performed on 235 patients, and the con-
ventional treatment strategy was chosen for 375 pa-
tients. We compared overall mortality, cardiac
mortality, and cardiac events (operative mortality,
cardiac mortality, repeat surgery, and urgent admis-
sion due to heart failure) between the 2 treatment
strategies in the propensity score–matched cohort.
RESULTS For the 207 propensity score–matched pairs,
early surgery had a lower risk of cardiac mortality
(hazard ratio [HR]: 0.109; 95% conﬁdence interval
[CI]: 0.014 to 0.836; p ¼ 0.033) and cardiac events (HR:
0.216; 95% CI: 0.083 to 0.558; p ¼ 0.002) than con-
ventional treatment. On Cox proportional hazard
model analysis, the risk of cardiac events was sig-
niﬁcantly lower in the early surgery group than in
the conventional treatment group in patients aged
50 years of age and older (HR: 0.221; 95% CI:
0.086 to 0.567; p ¼ 0.002), but not signiﬁcantly
different in those younger than 50 years of age
(p ¼ 0.20).
CONCLUSIONS Compared with conservative man-
agement, early surgery is associated with signiﬁcant
long-term reductions of cardiac mortality and cardiac
events in asymptomatic severe MR. These beneﬁts
were evident among patients age 50 years of age and
older (62).
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726Transcatheter Aortic Valve Replacement Using a
Self-Expanding Bioprosthesis in Patients With
Severe Aortic Stenosis at Extreme Risk for
Surgery
J.J. Popma, et al.
OBJECTIVES This study sought to evaluate the safety
and efﬁcacy of the CoreValve transcatheter heart
valve (THV) for the treatment of severe aortic stenosis
in patients at extreme risk for surgery.
BACKGROUND Untreated severe aortic stenosis is a
progressive disease with a poor prognosis. Transcatheter
aortic valve replacement (TAVR) with a self-expanding
bioprosthesis is a potentially effective therapy.
METHODS We performed a prospective, multicenter,
nonrandomized investigation evaluating the safety
and efﬁcacy of self-expanding TAVR in patients with
symptomatic severe aortic stenosis with prohibitive
risks for surgery. The primary endpoint was a
composite of all-cause mortality or major stroke at 12
months, which was compared with a pre-speciﬁed
objective performance goal (OPG).
RESULTS A total of 41 sites in the United States recruited
506 patients, of whom 489 underwent attempted treat-
ment with the CoreValve THV. The rate of all-cause
mortality or major stroke at 12 months was 26.0%
(upper 2-sided 95% conﬁdence bound: 29.9%) versus
43.0% with the OPG (p < 0.0001). Individual 30-day and
12-month events included all-cause mortality (8.4% and
24.3%, respectively) and major stroke (2.3% and 4.3%,
respectively). Procedural events at 30 days included
life-threatening/disabling bleeding (12.7%), major vas-
cular complications (8.2%), and need for permanent
pacemaker placement (21.6%). The frequency of
moderate or severe paravalvular aortic regurgitation was
lower 12 months after self-expanding TAVR (4.2%) than
at discharge (10.7%; p ¼ 0.004 for paired analysis).
CONCLUSIONS TAVR with a self-expanding
bioprosthesis was safe and effective in patients with
symptomatic severe aortic stenosis at prohibitive risk
for surgical valve replacement. (Safety and Efﬁcacy
Study of the Medtronic CoreValve System in the
Treatment of Symptomatic Severe Aortic Stenosis in
High Risk and Very High Risk Subjects Who Need
Aortic Valve Replacement; NCT01240902) (63).
Comprehensive Analysis of Mortality Among
Patients Undergoing TAVR: Results of the
PARTNER Trial
L.G. Svensson, et al.
BACKGROUND Patients with severe aortic stenosis
(AS) who were deemed too high risk or inoperable forconventional aortic valve replacement (AVR) in the
PARTNER (Placement of Aortic Transcatheter Valves)
trial were randomized to transcatheter aortic valve
replacement (TAVR) versus AVR (PARTNER-A arm) or
standard therapy (PARTNER-B arm).
OBJECTIVES This study compared when and how
deaths occurred after TAVR versus surgical AVR or
standard therapy.
METHODS The PARTNER-A arm included 244 trans-
femoral (TF) and 104 transapical (TA) TAVR patients,
and 351 AVR patients; the PARTNER-B arm included
179 TF-TAVR patients and 179 standard therapy pa-
tients. Deaths were categorized as cardiovascular,
noncardiovascular, or uncategorizable, and were
characterized by multiphase hazard modelling.
RESULTS In the PARTNER-A arm, the risk of death
peaked after randomization in the TA-TAVR and AVR
groups, falling to low levels commensurate with the
U.S. population within 3 months. Early risk was less in
TF-TAVR patients, resulting in initial superior survival;
between 12 and 18 months, risk increased, such that
within 2 years, TF-TAVR and AVR patients had similar
survival rates. Cardiovascular, noncardiovascular,
and uncategorizable deaths for TF-TAVR were 37%,
43%, and 20%, respectively, versus 22%, 41%, and
37%, respectively, for TA-TAVR and 33%, 43%,
and 24%, respectively, for AVR. In the PARTNER-B
arm, risk with standard therapy was 60% per year;
TF-TAVR reduced risk to 20% per year, resulting in
0.5 years of life added within 2.5 years.
CONCLUSIONS In inoperable AS patients, TAVR sub-
stantially reduced the risk of cardiovascular death. In
high-risk patients, TA-TAVR and AVR were associated
with elevated peri-procedural risk more than with
TF-TAVR, although cardiovascular death was higher
after TF-TAVR. Therefore, TF-TAVR should be consid-
ered the standard of care for severely symptomatic
inoperable patients or those at high risk
of noncardiovascular mortality after conventional sur-
gery. (THE PARTNER TRIAL: Placement of AoRTic
TraNscathetER Valve Trial; NCT00530894) (64).Predictors of Permanent Pacemaker Implantation
in Patients With Severe Aortic Stenosis
Undergoing TAVR: A Meta-Analysis
G.C.M. Siontis, et al.
BACKGROUND Atrioventricular (AV) conduction dis-
turbances requiring permanent pacemaker (PPM) im-
plantation may complicate transcatheter aortic valve
replacement (TAVR). Available evidence on predictors
of PPM is sparse and derived from small studies.
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727OBJECTIVES The objective of this study was to pro-
vide summary effect estimates for clinically useful
predictors of PPM implantation after TAVR.
METHODS We performed a systematic search for
studies that reported the incidence of PPM implanta-
tion after TAVR and that provided raw data for the
predictors of interest. Data on study, patient, and
procedural characteristics were abstracted. Crude risk
ratios (RRs) and 95% conﬁdence intervals for each
predictor were calculated by use of random effects
models. Stratiﬁed analyses by type of implanted valve
were performed.
RESULTS We obtained data from 41 studies that
included 11,210 TAVR patients, of whom 17% required
PPM implantation after intervention. The rate of PPM
ranged from 2% to 51% in individual studies (with a
median of 28% for the Medtronic CoreValve Revalving
System [MCRS] and 6% for the Edwards SAPIEN valve
[ESV]). The summary estimates indicated increased
risk of PPM after TAVR for men (RR: 1.23; p < 0.01); for
patients with ﬁrst-degree AV block (RR: 1.52; p < 0.01),
left anterior hemiblock (RR: 1.62; p < 0.01), or right
bundle branch block (RR: 2.89; p < 0.01) at baseline;
and for patients with intraprocedural AV block (RR:
3.49; p < 0.01). These variables remained signiﬁcant
predictors when only patients treated with the MCRS
bioprosthesis were considered. The data for ESV were
limited. Unadjusted estimates indicated a 2.5-fold
higher risk for PPM implantation for patients who
received theMCRS than for thosewho received the ESV.
CONCLUSIONS Male sex, baseline conduction distur-
bances, and intraprocedural AV block emerged as
predictors of PPM implantation after TAVR. This study
provides useful tools to identify high-risk patients and
to guide clinical decision making before and after
intervention (65).Incidence, Predictors, and Prognostic Impact of
Late Bleeding Complications After Transcatheter
Aortic Valve Replacement
P. Généreux, et al.
BACKGROUND The incidence and prognostic impact
of late bleeding complications after transcatheter
aortic valve replacement (TAVR) are unknown.
OBJECTIVES The aim of this study was to identify the
incidence, predictors, and prognostic impact of major
late bleeding complications (MLBCs) ($30 days) after
TAVR.
METHODS Clinical and echocardiographic outcomes of
patients who underwent TAVR within the randomized
cohorts and continued access registries in thePARTNER (Placement of Aortic Transcatheter Valves)
trial were analyzed after stratifying by the occurrence
of MLBCs. Predictors of MLBCs and their association
with 30-day to 1-year mortality were assessed.
RESULTS Among 2,401 patients who underwent
TAVR and survived to 30 days, MLBCs occurred in 142
(5.9%) at a median time of 132 days (interquartile
range: 71 to 230 days) after the index procedure.
Gastrointestinal complications (n ¼ 58 [40.8%]),
neurological complications (n ¼ 22 [15.5%]), and
traumatic falls (n ¼ 11 [7.8%]) were identiﬁed as the
most frequent types of MLBCs. Independent pre-
dictors of MLBCs were the presence of low hemoglo-
bin at baseline, atrial ﬁbrillation or ﬂutter at baseline
or 30 days, the presence of moderate or severe para-
valvular leak at 30 days, and greater left ventricular
mass at 30 days. MLBCs were identiﬁed as a strong
independent predictor of mortality between 30 days
and 1 year (adjusted hazard ratio: 3.91; 95% conﬁdence
interval: 2.67 to 5.71; p < 0.001).
CONCLUSIONS MLBCs after TAVR were frequent and
associated with increased mortality. Better individu-
alized and risk-adjusted antithrombotic therapy after
TAVR is urgently needed in this high-risk population.
(THE PARTNER TRIAL: Placement of AoRTic
TraNscathetER Valve Trial; NCT00530894) (66).
Bleeding Complications After Surgical Aortic
Valve Replacement Compared With
Transcatheter Aortic Valve Replacement: Insights
From the PARTNER I Trial (Placement of Aortic
Transcatheter Valve)
P. Généreux, et al.
OBJECTIVES This study sought to identify the inci-
dence, predictors, and prognostic impact of bleeding
complications (BC) after surgical aortic valve replace-
ment (SAVR) compared with transcatheter aortic valve
replacement (TAVR).
BACKGROUND Bleeding complications after SAVR
and TAVR are frequent and may be associated with an
unfavorable prognosis.
METHODS In the randomized controlled PARTNER
(Placement of Aortic Transcatheter Valve) I trial, 657
patients from cohort A (operable high risk) were
randomly assigned to SAVR or TAVR (transfemoral
[TF] if iliofemoral access was suitable or transapical
[TA] if not) and received the designated treatment.
First-generation Edwards SAPIEN valves and delivery
systems (Edwards Lifesciences, Irvine, California)
were used for TAVR, through a 22- or 24-F
sheath. The 30-day rates of major BC (modiﬁed
Valve Academic Research Consortium deﬁnitions),
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mortality were assessed.
RESULTS A total of 71 (22.7%), 27 (11.3%), and 9 (8.8%)
patients had major BC within 30 days of the procedure
after SAVR, TF-TAVR, and TA-TAVR, respectively
(p < 0.0001). SAVR was associated with a signiﬁcantly
higher 30-day rate of transfusion (17.9%) than either
TF-TAVR (7.1%) or TA-TAVR (4.8%; p < 0.0001).
Independent predictors of major BC were the
occurrence of major vascular complications and use
of intraprocedural hemodynamic support among
TF-TAVR patients, severe procedural complications
requiring conversion to open surgery among TA-TAVR
patients, and the presence of low hemoglobin at
baseline among SAVR patients. Major BC was
identiﬁed as the strongest independent predictor of
1-year mortality among the full cohort. However,
risk-adjusted analyses demonstrated a signiﬁcant
interaction between BC and treatment strategy with
respect to mortality, suggesting that BC after SAVR
have a greater impact on prognosis than after TAVR.
CONCLUSIONS Among high-risk aortic stenosis patients
enrolled in the PARTNER I randomized trial, BC were
more common after SAVR than after TAVR and were
also associated with a worse long-term prognosis. (THE
PARTNER TRIAL: Placement of AoRTic TraNscathetER
Valve Trial; NCT00530894) (67).Transcatheter Aortic Valve Replacement for
Severe Symptomatic Aortic Stenosis Using a
Repositionable Valve System: 30-Day Primary
Endpoint Results From the REPRISE II Study
I.T. Meredith AM, et al.
BACKGROUND Transcatheter aortic valve replace-
ment provides results comparable to those of surgery
in patients at high surgical risk, but complications can
impact long-term outcomes. The Lotus valve,
designed to improve upon earlier devices, is fully
repositionable and retrievable, with a unique seal to
minimize paravalvular regurgitation (PVR).
OBJECTIVES The prospective, single-arm, multicenter
REPRISE II study (REpositionable Percutaneous Replace-
ment of Stenotic Aortic Valve Through Implantation of
Lotus Valve System: Evaluation of Safety and
Performance) evaluated the transcatheter valve system
for treatment of severe symptomatic calciﬁc aortic valve
stenosis.
METHODS Patients (n ¼ 120; aortic annulus 19 to 27 mm)
considered by a multidisciplinary heart team to be at
high surgical risk received the valve transfemorally. The
primary device performance endpoint, 30-day meanpressure gradient, was assessed by an independent
echocardiographic core laboratory and compared with a
pre-speciﬁed performance goal. The primary safety
endpoint was 30-day mortality. Secondary endpoints
included safety/effectiveness metrics per Valve
Academic Research Consortium criteria.
RESULTS Mean age was 84.4 years, 57% of the patients
were female, and 76% were New York Heart Association
functional class III/IV. Mean aortic valve area was 0.7 
0.2 cm2. The valve was successfully implanted in all
patients, with no cases of valve embolization, ectopic
valve deployment, or additional valve implantation. All
repositioning (n ¼ 26) and retrieval (n ¼ 6) attempts
were successful; 34 patients (28.6%) received a perma-
nent pacemaker. The primary device performance
endpoint was met, because the mean gradient improved
from 46.4  15.0 mm Hg to 11.5  5.2 mmHg. At 30 days,
the mortality rate was 4.2%, and the rate of disabling
stroke was 1.7%; 1 (1.0%) patient had moderate PVR,
whereas none had severe PVR.
CONCLUSIONS REPRISE II demonstrates the safety
and effectiveness of the Lotus valve in patients with
severe aortic stenosis who are at high surgical risk.
The valve could be positioned successfully with min-
imal PVR. (REPRISE II: REpositionable Percutaneous
Replacement of Stenotic Aortic Valve Through Im-
plantation of Lotus Valve System - Evaluation of
Safety and Performance; NCT01627691) (68).
Temporal Changes in Interpapillary Muscle
Dynamics as an Active Indicator of Mitral Valve
and Left Ventricular Interaction in Ischemic Mitral
Regurgitation
K. Kalra, et al.
BACKGROUND Regional subpapillary myocardial
hypokinesis may impair lateral reduction in the
interpapillary muscle distance (IPMD) from diastole to
systole, and adversely affect mitral valve geometry
and tethering.
OBJECTIVES The goal of this study was to investigate
the impact of impaired lateral shortening in the
interpapillary muscle distance on mitral valve geom-
etry and function in ischemic heart disease.
METHODS To quantify ventricular size/shape, regional
myocardial contraction, lateral shortening of the IPMD,
mitral valve geometry, and severity of mitral regurgita-
tion, 67 patients with ischemic heart disease underwent
cardiac magnetic resonance imaging, and a correlation
analysis of measured parameters was performed. The
impact of reduced IPMD shortening on mitral valve (dys)
function was conﬁrmed in swine and in a physiological
computational mitral valve model.
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tole to systole was severely reduced in patients with
moderate/severe ischemic mitral regurgitation (9.6 
2.8 mm), but preserved in mild IMR (11.5  3.4 mm).
Left ventricular size and ejection fraction did not
differ between the groups. In swine with subpapillary
infarction and impaired IPMD, mitral regurgitation
was evident within 1 week, compared to those pigs
with a nonpapillary infarction and preserved IPMD. In
the controlled computational valve model, IPMD had
the maximal impact on regurgitation, and was exac-
erbated with additional annular dilation.
CONCLUSIONS By using cardiac magnetic resonance
imaging in humans, we demonstrated that it is the
impairment of lateral shortening between the papillary
muscles, and not passive ventricular size, that governs
the severity of mitral regurgitation. Loss of lateral
shortening of IPMD tethers the leaﬂet edges and im-
pairs their systolic closure, resulting in mitral regurgi-
tation, even in small ventricles. Understanding the
lateral dynamics of ventricular-valve interactions could
aid the development of new repair techniques for
ischemic mitral regurgitation (69).
The Evolution of Percutaneous Mitral Valve
Repair Therapy: Lessons Learned and
Implications for Patient Selection
R. Beigel, et al.
Mitral regurgitation (MR) is the most common valve
disease in the United States. However, a signiﬁcant
number of patients are denied surgery due to
increased age, poor ventricular function, or associated
comorbidities, putting them at high risk for adverse
events. Moreover, the beneﬁt of surgery for MR is
unclear in patients with functional (secondary) MR.
Recently, percutaneous repair of the mitral valve with
a particular device (MitraClip, Abbott, Menlo Park,
California) has emerged as a novel therapeutic option
for patients with secondary MR or those deemed to
be high risk for surgery. We review data from its
initial concept through clinical trials and current data
available from several registries. We focused on
lessons learned regarding adequate patient selection,
along with current and future perspectives on the use
of device therapy for the treatment of MR (70).
Percutaneous Approaches to Valve Repair for
Mitral Regurgitation
T. Feldman, et al.
Percutaneous therapy has emerged as an option
for treatment of mitral regurgitation for selected, pre-
dominantly high-risk patients. Most of the percutaneousapproaches are modiﬁcations of existing surgical
approaches. Catheter-based devices mimic these surgical
approaches with less procedural risk, due to their less-
invasive nature. Percutaneous annuloplasty can be
achieved indirectly via the coronary sinus or directly
from retrograde left ventricular access. Catheter-based
leaﬂet repair with the MitraClip (Abbott Laboratories,
Abbott Park, Illinois) is accomplished with an
implantable clip to mimic the surgical edge-to-edge
leaﬂet repair technique. A large experience with
MitraClip has been reported, and several other
percutaneous approaches have been successfully used in
smaller numbers of patients to demonstrate proof of
concept, whereas others have failed and are no longer
under development. There is increasing experience
in both trials and practice to begin to deﬁne the clinical
utility of percutaneous leaﬂet repair, and annuloplasty
approaches are undergoing signiﬁcant development.
Transcatheter mitral valve replacement is still in early
development (71).
Percutaneous Mitral Valve Repair for Mitral
Regurgitation in High-Risk Patients: Results of
the EVEREST II Study
D.D. Glower, et al.
BACKGROUND The EVEREST II (Endovascular Valve
Edge-to-Edge REpair STudy) High-Risk registry and
REALISM Continued Access Study High-Risk Arm are
prospective registries of patients who received the
MitraClip device (Abbott Vascular, Santa Clara,
California) for mitral regurgitation (MR) in the
United States.
OBJECTIVES The purpose of this study was to report
12-month outcomes in high-risk patients treated with
the percutaneous mitral valve edge-to-edge repair.
METHODS Patients with grades 3 to 4þ MR and a
surgical mortality risk of $12%, based on the Society of
Thoracic Surgeons risk calculator or the estimate of a
surgeon coinvestigator following pre-speciﬁed
protocol criteria, were enrolled.
RESULTS In the studies, 327 of 351 patients completed
12 months of follow-up. Patients were elderly (76  11
years of age), with 70% having functional MR and 60%
having prior cardiac surgery. The mitral valve device
reduced MR to #2þ in 86% of patients at discharge
(n ¼ 325; p < 0.0001). Major adverse events at 30
days included death in 4.8%, myocardial infarction
in 1.1%, and stroke in 2.6%. At 12 months, MR
was #2þ in 84% of patients (n ¼ 225; p < 0.0001).
From baseline to 12 months, left ventricular (LV)
end-diastolic volume improved from 161  56 ml
to 143  53 ml (n ¼ 203; p < 0.0001) and LV
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44 ml (n ¼ 202; p < 0.0001). New York Heart
Association functional class improved from 82% in
class III/IV at baseline to 83% in class I/II at 12
months (n ¼ 234; p < 0.0001). The 36-item Short
Form Health Survey physical and mental quality-of-
life scores improved from baseline to 12 months
(n ¼ 191; p < 0.0001). Annual hospitalization rate for
heart failure fell from 0.79% pre-procedure to 0.41%
post-procedure (n ¼ 338; p < 0.0001). Kaplan-Meier
survival estimate at 12 months was 77.2%.
CONCLUSIONS The percutaneous mitral valve device
signiﬁcantly reduced MR, improved clinical symp-
toms, and decreased LV dimensions at 12 months in
this high-surgical-risk cohort. (Endovascular Valve
Edge-to-Edge REpair STudy [EVERESTIIRCT];
NCT00209274) (72).
Percutaneous Mitral Valve Edge-to-Edge Repair:
In-Hospital Results and 1-Year Follow-Up of 628
Patients of the 2011–2012 Pilot European Sentinel
Registry
G. Nickenig, et al.
BACKGROUND The use of transcatheter mitral valve
repair (TMVR) has gained widespread acceptance in
Europe, but data on immediate success, safety, and
long-term echocardiographic follow-up in real-world
patients are still limited.
OBJECTIVES The aim of this multinational registry is
to present a real-world overview of TMVR use in
Europe.
METHODS The Transcatheter Valve Treatment
Sentinel Pilot Registry is a prospective, independent,
consecutive collection of individual patient data.
RESULTS A total of 628 patients (mean age 74.2  9.7
years, 63.1% men) underwent TMVR between January
2011 and December 2012 in 25 centers in 8 European
countries. The prevalent pathogenesis was functional
mitral regurgitation (FMR) (n ¼ 452 [72.0%]). The
majority of patients (85.5%) were highly symptomatic
(New York Heart Association functional class III or
higher), with a high logistic EuroSCORE (European Sys-
tem for Cardiac Operative Risk Evaluation) (20.4 
16.7%). Acute procedural success was high (95.4%) and
similar in FMR and degenerative mitral regurgitation
(p ¼ 0.662). One clip was implanted in 61.4% of patients.
In-hospital mortality was low (2.9%), without signiﬁcant
differences between groups. The estimated 1-year
mortality was 15.3%, which was similar for FMR and
degenerative mitral regurgitation. The estimated 1-year
rate of rehospitalization because of heart failure was
22.8%, signiﬁcantly higher in the FMR group (25.8% vs.12.0%, p[log-rank] ¼ 0.009). Paired echo-cardiographic
data from the 1-year follow-up, available for 368
consecutive patients in 15 centers, showed a persistent
reduction in the degree of mitral regurgitation at 1 year
(6.0% of patients with severe mitral regurgitation).
CONCLUSIONS This independent, contemporary reg-
istry shows that TMVR is associated with high imme-
diate success, low complication rates, and sustained
1-year reduction of the severity of mitral regurgita-
tion and improvement of clinical symptoms (73).Percutaneous Mitral Valve Repair With the
MitraClip System for Severe Mitral Regurgitation
in Patients With Surgical Mitral Valve
Repair Failure
C. Grasso, et al.
Surgical mitral valve repair (SMVR) is the preferred
intervention for patients with either symptomatic
severe mitral regurgitation (MR) or asymptomatic severe
MR and left ventricular dysfunction. The rate of
freedom from severe MR 10 years after SMVR, however,
is reported to be 70%, leading to a considerable number
of mitral valve reinterventions, which carry substantial
risk, particularly in elderly patients and in those with
signiﬁcant comorbidities (74).Improved Functional Status and Quality of Life in
Prohibitive Surgical Risk Patients With
Degenerative Mitral Regurgitation After
Transcatheter Mitral Valve Repair
D.S. Lim, et al.
BACKGROUND Surgical mitral valve repair (SMVR)
remains the gold standard for severe degenerative
mitral regurgitation (DMR). However, the results
with transcatheter mitral valve repair (TMVR) in
prohibitive-risk DMR patients have not been
previously reported.
OBJECTIVES This study aimed to evaluate treatment
of mitral regurgitation (MR) in patients with severe
DMR at prohibitive surgical risk undergoing TMVR.
METHODS A prohibitive-risk DMR cohort was
identiﬁed by a multidisciplinary heart team that
retrospectively evaluated high-risk DMR patients
enrolled in the EVEREST (Endovascular Valve Edge-
to-Edge Repair Study) II studies.
RESULTS A total of 141 high-risk DMR patients were
consecutively enrolled; 127 of these patients were
retrospectively identiﬁed as meeting the deﬁnition
of prohibitive risk and had 1-year follow-up (median:
1.47 years) available. Patients were elderly (mean
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Heart Association class III/IV), and at prohibitive
surgical risk (STS score: 13.2  7.3%). TMVR
(MitraClip) was successfully performed in 95.3%;
hospital stay was 2.9  3.1 days. Major adverse
events at 30 days included death in 6.3%, myocardial
infarction in 0.8%, and stroke in 2.4%. Through 1
year, there were a total of 30 deaths (23.6%), with no
survival difference between patients discharged with
MR #1þ or MR 2þ. At 1 year, the majority of
surviving patients (82.9%) remained MR #2þ at 1
year, and 86.9% were in New York Heart Association
functional class I or II. Left ventricular end-diastolic
volume decreased (from 125.1  40.1 ml to 108.5 
37.9 ml; p < 0.0001 [n ¼ 69 survivors with paired
data]). SF-36 quality-of-life scores improved and
hospitalizations for heart failure were reduced in
patients whose MR was reduced.
CONCLUSIONS TMVR in prohibitive surgical risk pa-
tients is associated with safety and good clinical out-
comes, including decreases in rehospitalization,
functional improvements, and favorable ventricular
remodeling, at 1 year. (Real World Expanded Multi-
center Study of the MitraClip System [REALISM];
NCT01931956) (75).Off-Pump Transapical Implantation of Artiﬁcial
Neo-Chordae to Correct Mitral Regurgitation:
The TACT Trial (Transapical Artiﬁcial Chordae
Tendinae) Proof of Concept
J. Seeburger, et al.
OBJECTIVES The goal of this study was to evaluate
the safety and performance of the NeoChord DS1000
system (NeoChord, Inc., Minneapolis, Minnesota).
BACKGROUND There is an increasing interest in
transcatheter mitral valve (MV) treatment. The Neo-
Chord DS 1000 system enables off-pump beating heart
transapical MV repair with implantation of artiﬁcial
neo-chordae.
METHODS Patients with severe mitral regurgitation
(MR) due to isolated posterior prolapse were included
in this TACT (Transapical Artiﬁcial Chordae Tendinae)
trial. All patients were scheduled for off-pump
transapical implantation of neo-chordae.
RESULTS Thirty patients at 7 centers were enrolled.
Major adverse events included 1 death due to post-
cardiotomy syndrome and concomitant sepsis and 1
minor stroke with the patient fully recovered at the
30-day follow-up visit. Additional patients ex-
perienced procedural major adverse events related to a
reoperation or conversion to standard of care. Acuteprocedural success (placement of at least 1 neo-chord
and reduction of MR from 3þ or 4þ to #2þ) was
achieved in 26 patients (86.7%). In 4 patients
neo-chordae were not placed for technical and/or
patient-speciﬁc reasons. These patients underwent
intraoperative (3 patients) or post-operative (1 patient)
standard MV repair. At 30 days, 17 patients maintained
an MR grade #2þ. Four patients who developed
recurrent MR were successfully treated with open MV
repair during 30-day follow-up. Results improved with
experience: durable reduction in MR to #2þ at 30 days
was achieved in 5 (33.3%) of the ﬁrst 15 patients and 12
(85.7%) of the last 14 patients.
CONCLUSIONS Off-pump transapical implantation of
artiﬁcial chordae to correct MR is technically safe and
feasible; however, it yields further potential for
improvement of efﬁcacy and durability. (Safety and
Performance Study of the NeoChord Device [TACT];
NCT01777815) (76).
Proximal Aortic Distensibility Is an Independent
Predictor of All-Cause Mortality and Incident CV
Events: The MESA Study
A. Redheuil, et al.
BACKGROUND The predictive value of ascending
aortic distensibility (AAD) for mortality and hard car-
diovascular disease (CVD) events has not been fully
established.
OBJECTIVES This study sought to assess the utility of
AAD to predict mortality and incident CVD events
beyond conventional risk factors in MESA (Multi-
Ethnic Study of Atherosclerosis).
METHODS AAD was measured with magnetic reso-
nance imaging at baseline in 3,675 MESA participants
free of overt CVD. Cox proportional hazards regression
was used to evaluate risk of death, heart failure (HF),
and incident CVD in relation to AAD, CVD risk factors,
indexes of subclinical atherosclerosis, and Framing-
ham risk score.
RESULTS There were 246 deaths, 171 hard CVD events
(myocardial infarction, resuscitated cardiac arrest,
stroke and CV death), and 88 HF events over a median
8.5-year follow-up. Decreased AAD was associated
with increased all-cause mortality with a hazard ratio
(HR) for the ﬁrst versus ﬁfth quintile of AAD of 2.7
(p ¼ 0.008) independent of age, sex, ethnicity, other
CVD risk factors, and indexes of subclinical
atherosclerosis. Overall, patients with the lowest
AAD had an independent 2-fold higher risk of hard
CVD events. Decreased AAD was associated with CV
events in low to intermediate- CVD risk individuals
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732with an HR for the ﬁrst quintile of AAD of 5.3 (p ¼ 0.03)
as well as with incident HF but not after full
adjustment.
CONCLUSIONS Decreased proximal aorta distensi-
bility signiﬁcantly predicted all-cause mortality and
hard CV events among individuals without overt
CVD. AAD may help reﬁne risk stratiﬁcation,
especially among asymptomatic, low- to
intermediate-risk individuals (77).
Transcatheter Implantation of Homologous “Off-
the-Shelf” Tissue-Engineered Heart Valves With
Self-Repair Capacity: Long-Term Functionality
and Rapid In Vivo Remodeling in Sheep
A. Driessen-Mol, et al.
OBJECTIVES This study sought to evaluate long-term
in vivo functionality, host cell repopulation, and
remodeling of “off-the-shelf” tissue engineered
transcatheter homologous heart valves.
BACKGROUND Transcatheter valve implantation has
emerged as a valid alternative to conventional sur-
gery, in particular for elderly high-risk patients.
However, currently used bioprosthetic transcatheter
valves are prone to progressive dysfunctional
degeneration, limiting their use in younger patients.
To overcome these limitations, the concept of tissue
engineered heart valves with self-repair capacity has
been introduced as next-generation technology.
METHODS In vivo functionality, host cell repopula-
tion, and matrix remodeling of homologous trans-
catheter tissue-engineered heart valves (TEHVs) was
evaluated up to 24 weeks as pulmonary valve
replacements (transapical access) in sheep (n ¼ 12).
As a control, tissue composition and structure were
analyzed in identical not implanted TEHVs (n ¼ 5).
RESULTS Transcatheter implantation was successful
in all animals. Valve functionality was excellent dis-
playing sufﬁcient leaﬂet motion and coaptation with
only minor paravalvular leakage in some animals.
Mild central regurgitation was detected after 8 weeks,
increasing to moderate after 24 weeks, correlating to a
compromised leaﬂet coaptation. Mean and peak
transvalvular pressure gradients were 4.4  1.6
mm Hg and 9.7  3.0 mm Hg, respectively. Signiﬁcant
matrix remodeling was observed in the entire valve
and corresponded with the rate of host cell
repopulation.
CONCLUSIONS For the ﬁrst time, the feasibility and
long-term functionality of transcatheter-based
homologous off-the-shelf tissue engineered heart
valves are demonstrated in a relevant pre-clinical
model. Such engineered heart valves may representan interesting alternative to current prostheses
because of their rapid cellular repopulation, tissue
remodeling, and therewith self-repair capacity. The
concept of homologous off-the-shelf tissue
engineered heart valves may therefore substantially
simplify previous tissue engineering concepts toward
clinical translation (78).VASCULAR MEDICINE
Local Stiffness of the Carotid and Femoral Artery
Is Associated With Incident Cardiovascular
Events and All-Cause Mortality:
The Hoorn Study
T.T. van Sloten, et al.
OBJECTIVES This study sought to investigate the as-
sociation of local and segmental arterial stiffness with
incident cardiovascular events and all-cause
mortality.
BACKGROUND The association of different stiffness
indices, in particular of carotid, brachial, and femoral
stiffness, with cardiovascular disease and mortality is
currently unknown.
METHODS In a population-based cohort (n ¼ 579,
mean age 67 years, 50% women, 23% with type 2
diabetes [by design]), we assessed local stiffness
of carotid, femoral, and brachial arteries (by
ultrasonography), carotid-femoral pulse wave
velocity (cfPWV), aortic augmentation index, and
systemic arterial compliance.
RESULTS After a median follow-up of 7.6 years, 130
participants had a cardiovascular event and 96 had
died. The hazard ratios (HRs) (95% conﬁdence
intervals [CIs]) per 1 SD for cardiovascular events and
all-cause mortality, respectively, were HR: 1.22 (95%
CI: 0.95 to 1.56) and 1.51 (95% CI: 1.11 to 2.06) for lower
carotid distensibility; HR: 1.19 (95% CI: 1.00 to 1.41)
and 1.28 (95% CI: 1.07 to 1.53) for higher carotid elastic
modulus; HR: 1.08 (95% CI: 0.88 to 1.31) and 1.43 (95%
CI: 1.10 to 1.86) for lower carotid compliance; HR: 1.39
(95% CI: 1.06 to 1.83) and 1.27 (95% CI: 0.90 to 1.79)
for lower femoral distensibility; HR: 1.25 (95% CI: 0.96
to 1.63) and 1.47 (95% CI: 1.01 to 2.13) for lower
femoral compliance; and HR: 1.56 (95% CI: 1.23 to 1.98)
and 1.13 (95% CI: 0.83 to 1.54) for higher cfPWV. These
results were adjusted for age, sex, mean arterial
pressure, and cardiovascular risk factors. Mutual
adjustments for each of the other stiffness indices did
not materially change these results. Brachial stiffness,
augmentation index, and systemic arterial compliance
were not associated with cardiovascular events or
mortality.
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are independently associated with incident cardio-
vascular events and all-cause mortality. The strength
of these associations with events may differ per
stiffness parameter (79).
Thoracic Aortic Aneurysm and Dissection
J.Z. Goldﬁnger, et al.
Aortic dissection is the most devastating complication of
thoracic aortic disease. In the more than 250 years since
thoracic aortic dissection was ﬁrst described, much has
been learned about diseases of the thoracic aorta. In this
review, we describe normal thoracic aortic size; risk
factors for dissection, including genetic and inﬂam-
matory conditions; the underpinnings of genetic
diseases associated with aneurysm and dissection,
including Marfan syndrome and the role of transforming
growth factor beta signaling; data on the role for medical
therapies in aneurysmal disease, including beta-blockers,
angiotensin receptor blockers, and angiotensin-
converting enzyme inhibitors; prophylactic surgery for
aneurysm; surgical techniques for the aortic root; and
surgical and endovascular management of aneurysm and
dissection for different aortic segments (80).
Outcomes of Acute Type A Dissection Repair
Before and After Implementation of a
Multidisciplinary Thoracic Aortic Surgery
Program
N.D. Andersen, et al.
OBJECTIVES The purpose of this study was to
compare the results of acute type A aortic dissection
(ATAAD) repair before and after implementation of a
multidisciplinary thoracic aortic surgery program
(TASP) at our institution, with dedicated high-volume
thoracic aortic surgeons, a multidisciplinary approach
to thoracic aortic disease management, and a
standardized protocol for ATAAD repair.
BACKGROUND Outcomes of ATAAD repair may be
improved when operations are performed at special-
ized high-volume thoracic aortic surgical centers.
METHODS Between 1999 and 2011, 128 patients un-
derwent ATAAD repair at our institution. Records of
patients who underwent ATAAD repair 6 years before
(n ¼ 56) and 6 years after (n ¼ 72) implementation of
the TASP were retrospectively compared. Expected
operative mortality rates were calculated using the
International Registry of Acute Aortic Dissection pre-
operative prediction model.
RESULTS Baseline risk proﬁles and expected opera-
tive mortality rates were comparable between patientswho underwent surgery before and after imple-
mentation of the TASP. Operative mortality before
TASP implementation was 33.9% and was statistically
equivalent to the expected operative mortality rate of
26.0% (observed-to-expected mortality ratio 1.30;
p ¼ 0.54). Operative mortality after TASP imple-
mentation fell to 2.8% and was statistically improved
compared with the expected operative mortality rate
of 18.2% (observed-to-expected mortality ratio 0.15;
p ¼ 0.005). Differences in survival persisted over long-
term follow-up, with 5-year survival rates of 85%
observed for TASP patients compared with 55% for
pre-TASP patients (p ¼ 0.002).
CONCLUSIONS ATAAD repair can be performed with
results approximating those of elective proximal
aortic surgery when operations are performed by a
high-volume multidisciplinary thoracic aortic surgery
team. Efforts to standardize or centralize care of
patients undergoing ATAAD are warranted (81).
How Does the Ascending Aorta Geometry Change
When It Dissects?
B. Rylski, et al.
OBJECTIVES The purpose of this study is to delineate
changes in aortic geometry and diameter due to
dissection.
BACKGROUND Aortic diameter is the major criterion
for elective ascending aortic replacement for dilated
ascending aortas to prevent aortic dissection. How-
ever, recommendations are made on the basis of
clinical experience and observation of diameters of
previously dissected aortas.
METHODS Six tertiary centers on 2 continents
reviewed their acute aortic dissection type A data-
bases, which contained 1,821 patients. Included were
all non-Marfan patients with nonbicuspid aortic
valves who had undergone computed tomography
angiography <2 years before and within 12 h after
aortic dissection onset. Aortic geometry before and
after dissection onset were compared.
RESULTS Altogether, 63 patients were included (27
spontaneous and 36 retrograde dissections, median
age 68 [57; 77] years; 54% were men). In all but 1 pa-
tient, maximum ascending aortic diameter was <55
mm before aortic dissection onset. The largest in-
crease in diameter and volume induced by the
dissection were observed in the ascending aorta (40.1
[36.6; 45.3] mm vs. 52.9 [46.1; 58.6] mm, þ12.8 mm;
p < 0.001; 124.0 [90.8; 162.5] cm3 vs. 171.0 [147.0;
197.0] cm3, þ47 cm3; p < 0.001). Mean aortic arch
diameter increased from 39.8 (30.5; 42.6) mm to 46.4
(42.0; 51.6) mm (þ6.6 mm; p < 0.001) and descending
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34.9 (30.9; 39.5) mm (þ3.7 mm; p < 0.001). Changes in
thoracic aorta geometry were similar for spontaneous
and retrograde etiology.
CONCLUSIONS Geometry of the thoracic aorta is
affected by aortic dissection, leading to an increase in
diameter that is most pronounced in the ascending
aorta. Both spontaneous and retrograde dissection
result in similar aortic geometry changes (82).
Coronary Artery Manifestations of
Fibromuscular Dysplasia
K.C. Michelis, et al.
Fibromuscular dysplasia (FMD) involving the coronary
arteries is an uncommon but important condition that
can present as acute coronary syndrome, left
ventricular dysfunction, or potentially sudden cardiac
death. Although the classic angiographic “string of
beads” that may be observed in renal artery FMD does
not occur in coronary arteries, potential manifestations
include spontaneous coronary artery dissection, distal
tapering or long, smooth narrowing that may represent
dissection, intramural hematoma, spasm, or tortuosity.
Importantly, FMD must be identiﬁed in at least one
other noncoronary arterial territory to attribute any
coronary ﬁndings to FMD. Although there is limited
evidence to guide treatment, many lesions heal
spontaneously; thus, a conservative approach is
generally preferred. The etiology is poorly understood,
but there are ongoing efforts to better characterize
FMD and deﬁne its genetic and molecular basis. This
report reviews the clinical course of FMD involving the
coronary arteries and provides guidance for diagnosis
and treatment strategies (83).
Paradoxical Embolism
S. Windecker, et al.
Paradoxical embolism is an important clinical entity
among patients with venous thromboembolism in the
presence of intracardiac or pulmonary shunts. The
clinical presentation is diverse and potentially life-
threatening. Although the serious nature and
complications of paradoxical embolism are recognized,
the disease entity is still rarely considered and remains
under-reported. This paper provides an overview on
the different clinical manifestations of paradoxical
embolism, describes the diagnostic tools for the
detection of intracardiac and pulmonary shunts, re-
views therapeutic options, and summarizes guideline
recommendations for the secondary prevention of
paradoxical embolism (84).Cor Pulmonale Parvus in Chronic Obstructive
Pulmonary Disease and Emphysema:
The MESA COPD Study
S.M. Kawut, et al.
BACKGROUND The classic cardiovascular complica-
tion of chronic obstructive pulmonary disease (COPD)
is cor pulmonale or right ventricular (RV) enlarge-
ment. Most studies of cor pulmonale were conducted
decades ago.
OBJECTIVES This study sought to examine RV
changes in contemporary COPD and emphysema using
cardiac magnetic resonance (CMR) imaging.
METHODS We performed a case-control study nested
predominantly in 2 general population studies of 310
participants with COPD and control subjects 50 to 79
years of age with $10 pack-years of smoking who were
free of clinical cardiovascular disease. RV volumes and
mass were assessed using magnetic resonance imaging.
COPD and COPD severity were deﬁned according to
standard spirometric criteria. The percentage of
emphysema was deﬁned as the percentage of lung
regions <950 Hounsﬁeld units on full-lung computed
tomography; emphysema subtypes were scored by
radiologists. Results were adjusted for age, race/
ethnicity, sex, height, weight, smoking status, pack-
years, systemic hypertension, and sleep apnea.
RESULTS Right ventricular end-diastolic volume
(RVEDV) was reduced in COPD compared with control
subjects (7.8 ml; 95% conﬁdence interval: 15.0
to 0.5 ml; p ¼ 0.04). Increasing severity of COPD was
associated with lower RVEDV (p ¼ 0.004) and lower RV
stroke volume (p < 0.001). RV mass and ejection
fraction were similar between the groups. A greater
percentage of emphysema also was associated with
lower RVEDV (p ¼ 0.005) and stroke volume (p < 0.001),
as was the presence of centrilobular and paraseptal
emphysema.
CONCLUSIONS RV volumes are lower without signif-
icant alterations in RV mass and ejection fraction in
contemporary COPD, and this reduction is related to
the greater percentage of emphysema on computed
tomography (85).
Multiparametric Cardiovascular Magnetic
Resonance Assessment of Cardiac Allograft
Vasculopathy
C.A. Miller, et al.
OBJECTIVES This study sought to evaluate the diag-
nostic performance of multiparametric cardiovascular
magnetic resonance (CMR) for detecting cardiac allo-
graft vasculopathy (CAV) using contemporary invasive
J A C C V O L . 6 5 , N O . 7 , 2 0 1 5 Fuster
F E B R U A R Y 2 4 , 2 0 1 5 : 7 0 1 – 3 7 Highlights of the Year
735epicardial artery and microvascular assessment tech-
niques as reference standards, and to compare the
performance of CMR with that of angiography.
BACKGROUND CAV continues to limit the long-term
survival of heart transplant recipients. Coronary
angiography has a Class I recommendation for CAV
surveillance and annual or biannual surveillance
angiography is performed routinely in most centers.
METHODS All transplant recipients referred for surveil-
lanceangiographyatasingleUKcenterovera2-yearperiod
were prospectively screened for study eligibility. Patients
prospectively underwent coronary angiography followed
by coronary intravascular ultrasound, fractional ﬂow
reserve, and index of microcirculatory resistance. Within
1 month, patients underwent multiparametric CMR,
including assessment of regional and global ventricular
function, absolute myocardial blood ﬂow quantiﬁcation,
and myocardial tissue characterization. In addition, 10
healthy volunteers underwent CMR.RESULTS Forty-eight patients were recruited, median
7.1 years (interquartile range: 4.6 to 10.3 years) since
transplantation. The CMR myocardial perfusion
reserve was the only independent predictor of both
epicardial (b ¼ 0.57; p < 0.001) and microvascular
disease (b ¼ 0.60; p < 0.001) on stepwise multivari-
able regression. The CMR myocardial perfusion
reserve signiﬁcantly outperformed angiography for
detecting moderate CAV (area under the curve, 0.89
[95% conﬁdence interval (CI): 0.79 to 1.00] vs. 0.59
[95% CI: 0.42 to 0.77]; p ¼ 0.01) and severe CAV (area
under the curve, 0.88 [95% CI: 0.78 to 0.98] vs. 0.67
[95% CI: 0.52 to 0.82]; p ¼ 0.05).
CONCLUSIONS CAV, including epicardial and micro-
vascular components, can be detected more accu-
rately using noninvasive CMR-based absolute
myocardial blood ﬂow assessment than with invasive
coronary angiography, the current clinical surveillance
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